20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 1
A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE 
SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL 
CONJUGATE VACCINE IN ADULTS 60 THROUGH 64 YEARS OF AGE
Investigational Product Number: PF-06482077
Investigational Product Name: 20-valent Pneumococcal Conjugate Vaccine
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:Not applicable (N/A)
Protocol Number: B7471002
Phase: 2CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 2Document History
Document Version Date Summary of Changes
Original protocol 20July 2017 Not applicab le (N/A)

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....7
APPENDICES ..................................................................................................................... ......7
SCHEDULE OF AC TIVITIES................................................................................................12
1. INTRODUCTION ...............................................................................................................1 5
1.1. Indica tion................................................................................................................ .15
1.2. Background and Rationale ......................................................................................15
1.2.1. Pneumococcal Disease................................................................................151.2.2. Vaccines to Prevent Pneumococcal Disease...............................................16
1.2.2.1. Pneumococcal Polysaccharide Vaccines...................................161.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines .................171.2.2.3. Rationale for 20vPnC................................................................18
2. STUDY OBJECTIVES AND ENDPOINTS.......................................................................19
2.1. Primary Objective and Endpoints ...........................................................................19
2.1.1. Primary Objective.......................................................................................192.1.2. Primary Endpoints ......................................................................................19
2.2. Secondary Objective and Endpoints .......................................................................20
2.2.1. Secondary Objective...................................................................................202.2.2. Secondary Endpoints ..................................................................................20
3. STUDY DESIGN................................................................................................................ .20
3.1. Duration of Subject Participation............................................................................223.2. Duration of Study....................................................................................................223.3. Number of Subjects.................................................................................................22
4. SUBJECT ELIGIBILITY CRITERIA.................................................................................22
4.1. Inclusion Criteria.....................................................................................................23
4.2. Exclusion Criteria....................................................................................................234.3. Temporary D elay Cr iteria .......................................................................................25CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 44.3.1. Criteria for Temporaril y Dela ying Vaccine Administration (Visits 1 
and 2) ...............................................................................................................25
4.3.2. Criteria for Temporaril y Dela ying Blood Draw (Visits 1, 2, 3, and 5) ......25
4.4. L ifesty le Requirements ...........................................................................................25
4.4.1. Contraception ..............................................................................................25
4.5. Sponsor’s Qualified Medical Personnel ..................................................................26
5. INVESTIGAT IONAL P RODUCTS ...................................................................................27
5.1. Allocation to I nvestigational Product ......................................................................27
5.2. Blinding of the Site Personnel .................................................................................27
5.3. Blinding of the Sponsor...........................................................................................28
5.4. Breaking the Blind
................................................................
..................................28
5.5. Subject Compliance .................................................................................................28
5.6. I nvestigational Product Supplies .............................................................................28
5.6.1. Dosage Form(s) and Packaging..................................................................29
5.6.2. Preparation and Dispensing ................................
........................................29
5.7. Administrati on................................................................
.........................................30
5.8. I nvestigational Product Storage ..............................................................................30
5.9. I nvestigational Product Accountabilit y...................................................................31
5.9.1. Destruction of Investigational Product Supplies
........................................31
5.10. Concomitant Treatment(s) .....................................................................................31
5.10.1. Prohibited During the Study ................................
.....................................31
5.10.2. Permitted During the Study ......................................................................32
5.10.3. Recording Concomitant Treatments.........................................................32
6. STUDY PROCEDURES ................................ ................................ ................................ .....32
6.1. Visit 1 (Vaccination 1 – Day 1) ................................ ................................ .............. 32
6.2. Visit 2 (V accination 2 – 28 to 35 Day s After Visit 1) ................................ ............. 34
6.3. Visit 3 (Follow -up Vaccination 2 –28 to 35 Day s After Visit 2) ...........................35
6.4. Visi t 4 (6- Month Safety  Collection by  Telephone – 168 to 196 Day s After 
Visit 1) ................................
.......................................................................................35
6.5. Visit 5 (Persistence Blood Draw and 12 -Month Safety  Collection –350 to 
378 Day s After Visit 1) .............................................................................................36
6.6. Unscheduled Visits ..................................................................................................36

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 56.7. Subject Withdrawal .................................................................................................37
7. ASSESSMENTS ..................................................................................................................39
7.1. Safet y Parameters ....................................................................................................39
7.1.1. Subject Electronic Diary .............................................................................40
7.1.2. Grading Scale for Prompted Events ...........................................................40
7.1.2.1. L ocal Reactions .........................................................................40
7.1.2.2. Sy stemic Events ........................................................................41
7.1.2.3. Fever ..........................................................................................42
7.1.2.4. Use of Antip yretic/Pain Medication ..........................................43
7.2. I mmunogenicity ................................
......................................................................43
7.3. Biological Samples ..................................................................................................43
8. ADVERSE EVENT REP ORTI NG......................................................................................44
8.1. Requireme nts...........................................................................................................44
8.1.1. Additional Details on Recording Adverse Events on the CRF ...................45
8.1.2. Eliciting Adverse Event Information ..........................................................45
8.1.3. Withdrawal from the Study  due to Adverse Events (see also the 
Subject Withdrawal Section) ...........................................................................45
8.1.4. Time Period for Collecting A E/SAE I nformation ......................................45
8.1.4.1. Reporting SAEs to Pfizer Safety ...............................................46
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF
...................46
8.1.5. Causality  Assessment .................................................................................46
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities ..................46
8.2. Definitions
................................................................
...............................................47
8.2.1. Adverse Events ...........................................................................................47
8.2.2. Abnormal Test Findings .............................................................................48
8.2.3. Serious Adverse Events ................................
..............................................48
8.2.4. Hospitalization ............................................................................................49
8.3. Severity  Assessment ................................................................................................50
8.4. Special Situations ....................................................................................................51
8.4.1. Protocol-Specified Serious Adverse Events
...............................................51
8.4.2. Potential Cases of Drug -Induced Liver Injury............................................51

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 68.4.3. Exposure to the Investigational Product during Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................52
8.4.3.1. Exposure during Pregnancy ......................................................538.4.3.2. Exposure during Breastfeeding .................................................548.4.3.3. Occupational Exposure .............................................................54
8.4.4. Medication Errors and Lack of Efficacy ....................................................55
8.4.4.1. Medication Errors......................................................................558.4.4.2. Lack of Efficacy........................................................................56
8.5. Medical Device Complaint Reporting Requirements .............................................56
9. DATA ANALYSIS/STATISTICAL METHODS...............................................................56
9.1. Sample Size Determination.....................................................................................569.2. Analysis Populations ...............................................................................................569.3. Immunogenicity Analysis .......................................................................................579.4. Safety Analysis........................................................................................................58
9.5. Analysis Timing ......................................................................................................58
10. QUALITY CONTROL AND QUALITY ASSURANCE.................................................59
11. DATA HANDLING AND RECORD KEEPING .............................................................60
11.1. Case Report Forms/Electronic Data Record .........................................................6011.2. Record Retention...................................................................................................60
12. ETHICS..................................................................................................................... .........61
12.1. Institutional Review Board/Ethics Committee......................................................6112.2. Ethical Conduct of the Study ................................................................................6112.3. Subject Information and Consent..........................................................................6112.4. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................6 2
13. DEFINITION OF END OF TRIAL...................................................................................62
13.1. End of Trial in the Participating Country..............................................................62
14. SPONSOR DISCONTI NUATION CRITERIA ................................................................62
15. PUBLICATION OF STUDY RESULTS ..........................................................................62
15.1. Communication of Results by Pfizer ....................................................................6215.2. Publications by Investigators ................................................................................63CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 716. REFERENCES ..................................................................................................................65
LIST OF TABLES
Table 1. Time Points for Key  Safety  and Immunogenicity  Objectives by  
Investigational Product .........................................................................................21
Table 2. Grading Scales for Local Reactions .....................................................................41
Table 3. Grading Scales for Sy stemic Events .....................................................................42
Table 4. Ranges for Fe ver...................................................................................................42
APPENDICES
Appendix 1.................................................................
..............................................................73

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 8PROTOCOL SUMMARY
Backgr ound and Rationale
Streptococcus pneumoniae are gram -positive encapsulated cocci that have been aleading 
cause of bacter emia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and 
continue to be a major global public health concern. Serious pneumococcal disease may  
occur at an y age; however, children <5 years and adults  65 years of age are at particularly  
increased risk.  Individuals with certain comorbidities and immunocompromising conditions 
are also at risk.  Centers for Disease Control an d Prevention (CDC) data estimated that in 
2015 there were 29,500 cases and 3350 deaths due to invasive pneumococcal disease (I PD) 
in the United States.  I n 2008, the World Health Organization (WHO) estimated that 
1.6million people die from pneumococcal di sease each year.  Spneumoniae remains an 
important cause of serious disease in the United States and worldwide.
The poly saccharide capsule has been identified as an important virulence factor for this 
pathogen. While more than 95 pneumococcal seroty pes d ifferentiated by  their capsular 
polysaccharide composition have been identified , only a subset of serot ypes are more 
commonly  associated with severe disease.  Pneumococcal disease can be prevented with 
polysaccharide -based vaccines that induce antibody  responses with functional 
(opsonophagocy tic) activity  and target the capsular serot ypes res ponsible for disease.  
Pneumococcal vaccines ,such as the licensed 23 -valent pneumococcal polysaccharide 
vaccine (PPSV23), containing free pol ysaccharide s for23 pneumo coccal seroty pes, elicit a 
T
-cell–independent immune response .  These vaccines are poorl y immunogenic for man y of 
the serot ypes contained in the vaccine in children less than 2 y ears of age , 
immunocompromised populations, and older adults . They  do not ind
uce memory  responses 
in any  population , and have l imited or no protection against nonbacteremic disease, including 
community -acquired pneumonia (CAP) . Pneumococcal conjugate vaccines, which contain 
capsular polysaccharide scovalentl y linked to a protein c arrier, elicit a T -cell–dependent 
immune response inducing protective responses in y oung children, older adults, and 
populations with high
-risk conditions. 
Prevnar(7-valent pneumococcal conjugate vaccine) , which was licensed in the United 
States in 2000 , and Prevnar 13(13-valent pneumococcal conjugate vaccine [13vPnC]) , 
which was licensed in the United States in 2010, are pneumococcal conjugate vaccines 
containing 7 and 13, respectivel y,pneumococcal capsular polysaccharide sindividually
conjugated to cross -reactive material 
197 (CRM 197), a nontoxic variant of diphtheria toxin.  
These vaccines target seroty pes that caused the majority of pneumococcal disease in infants 
and older adults at the time of their introduction.  They  have demonstrated 
efficacy /
effectiveness against vaccine- type (VT) IPD, AOM, and pneumonia andthe ability  
to reduce nasophary ngeal carriage and transmission, resulting in indirect beneficial effects.  

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 9Pfizer is developing a new 20-valent pneumococcal conjugate vaccine (20vPnC) candidate to 
further expand protection against the global burden of vaccine-preventable pneumococcal disease in children and adults over that of Prevnar 13. 20vPnC has the same composition as Prevnar 13, but contains an additional 7 pneumococcal conjugates to protect against serotypes responsible for a substantial burden of remaining pneumococcal disease.  20vPnC uses the same platform as Prevnar and Prevnar 13 and contains components that have undergone extensive clinical research. A Phase 1 study is being conducted in healthy adults 18 to 49 years of age to support further development of 20vPnC. The purpose of the proposed Phase 2 study in older adults is to generate a safety and immunogenicity data set with 20vPnC to support and inform the design of the Phase 3 clinical development program for adults.
Study Design
This is a Phase 2, multicenter, randomized, active-controlled, double-blind study with a 
2-arm parallel design.  A total of 440 adults 60 through 64 years of age with no history of 
pneumococcal vaccination will be enrolled and randomized equally to receive an initial vaccination with either:
•a single dose of 20vPnC followed 1 month later by saline (placebo) administration in 
the active vaccine group (20vPnC/saline group), or
•a single dose of 13vPnC followed 1 month later by a dose of PPSV23 in the control 
group (13vPnC/PPSV23 group).
13vPnC will serve as a control for safety, as well as immunogenicity of the 13 serotypes in 
common with 20vPnC. PPSV23 will serve as a control for immunogenicity of the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) in 20vPnC.
Blood samples will be collected on the day of investigational product administration prior to 
each study vaccination (Vaccination 1 and Vaccination 2), 1 month after Vaccination 2, and 12 months after Vaccination 1 for immunogenicity assessments.  Prompted local reactions at the injection site and prompted systemic events will be collected daily for 10 and 7 days,respectively, after Vaccination 1.  Adverse events (AEs) occurring from signed informed consent through 1 month after Vaccination 2 will be collected and serious adverse events (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) will be collected from signed informed consent through 12 months after Vaccination 1.
 
 
 
 
 
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 10 
Primary Objective and Endpoints
Primary Objective
•To describe the safety profile of 20vPnC in the study population.
Primary Endpoints
•Proportions of subjects reporting prompted local reactions within 10 days after 
vaccination (redness, swelling, and pain at the injection site).
•Proportions of subjects reporting prompted systemic events within 7 days after 
vaccination (fever, headache, fatigue, muscle pain, and joint pain).
•Proportions of subjects reporting adverse events (AEs) within 1 month after vaccination.
•Proportions of subjects reporting serious adverse events (SAEs) and newly diagnosed 
chronic medical conditions (NDCMCs) within 6 months and 12 months after vaccination.
Secondary Objective and Endpoints
Secondary Objective
•To describe the immunogenicity of 20vPnC in the study population.
Secondary Endpoints
•Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers 
(GMTs) 1 month after vaccination.
•Pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs) from before 
vaccination to 1 month after vaccination.
CCICCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 11Statistical Methods
An analysis of safety and immunogenicity data will be conducted when data are available as 
described in Section 9 and the statistical analysis plan (SAP).  All analyses will be 
descriptive.  No formal hypothesis tests between vaccine groups are planned; therefore, no power calculations for comparison of vaccine groups are included; however, the probabilities of at least 1 AE are calculated for range of assumed true event rates.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 12SCHEDULE OF ACTIVITI ES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the Study  Procedures and 
Assessments sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the schedule of activities table , in orde r to 
conduct evaluations or assessments required to protect the well -being of the subject.
Visit Number 1 2 3 4 5
Visit Description Vaccination 1 Vaccination 2 Follow -up 
Vaccination 26-Month Safety 
CollectionPersistence 
Blood Draw and 
12-Month 
Safety 
Collection
Visit Type Clinic Visit Clinic Visit Clinic Visit Telephone 
ContactClinic Visit
Visit Window (Days) Day 1 28 to 35 Days
After Visit 128 to 35 Days 
After Visit 2168 to 196 Days
After Visit 1350to 378Days 
After Visit 1
Obtain informed consent X
Record demography X
Obtain medical history data and record tobacco usage X
Perform physical examination and measure height and 
weightX
Measure prevaccination oral temperature X X
Contraception check, if applicableaX X X
Record nonstudy vaccinations and concomitant medicationsbX X X X X
Revie w inclusion and exclusion criteria X
Revie w continued eligibility X X X
Revie w temporary  delay criteria X X X X
Assign a subject number X

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 13Visit Number 1 2 3 4 5
Visit Description Vaccination 1 Vaccination 2 Follow-up 
Vaccination 26-Month Safety 
CollectionPersistence 
Blood Draw and 
12-Month 
Safety 
Collection
Visit Type Clinic Visit Clinic Visit Clinic Visit Telephone 
ContactClinic Visit
Visit Window (Days) Day 1 28 to 35 Days
After Visit 128 to 35 Days 
After Visit 2168 to 196 Days
After Visit 1350 to 378 Days 
After Visit 1
Assign randomization number X
Obtain blood sample (~30 or ~50 mL per blood sample) Xc,dXc,eXdX
Administer investigational vaccine (20vPnC/saline or 
13vPnC /PPSV23)X
(20vPnC or 
13vPnC)Xf
(saline or 
PPSV23)
Assess and record acute reactions for at least 30 minutes after investigational vaccine administrationXX
Provide subject with an e-diary, thermometer and measuring 
device and instruct how to collect prompted local reactions through Day 10 and systemic events through Day 7
gX
Review and/or collect e-diaryhXX
Record and report adverse eventsiX----------------------------------------XC
CI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 14Visit Number 1 2 3 4 5
Visit Description Vaccination 1 Vaccination 2 Follow-up 
Vaccination 26-Month Safety 
CollectionPersistence 
Blood Draw and 
12-Month 
Safety 
Collection
Visit Type Clinic Visit Clinic Visit Clinic Visit Telephone 
ContactClinic Visit
Visit Window (Days) Day 1 28 to 35 Days
After Visit 128 to 35 Days 
After Visit 2168 to 196 Days
After Visit 1350 to 378 Days 
After Visit 1
Record and report serious adverse events and newly 
diagnosed chronic medical conditionsjX-----------------------------------------X
a. The investigator or designee will inform the subject of the need to use highly effective contraception consistently and corre ctly until 28 days after vaccine 
administration and document the conversation and the subject’s affirmation in the subject’s chart.
b. Record nonstudy vaccinations and concomitant medications as described in Section 5.10.3 .
c. Blood sample will be collected prior to vaccination.
d. Obtain blood sample (~30 mL) for immunologic assessments.
f. Subjects who received 20vPnC on Day 1 will receive saline; subjects who received 13vPnC on Day 1 will receive PPSV23.
g. Subjects will record prompted local reactions and systemic events in an electronic diary (e-diary) for the 10 and 7 days, res pectively, following the first 
vaccination. Subjects will be requested to contact the study staff if they experience redness or swelling measuring ≥21 caliper units or severe pain at the 
injection site or a fever >104.0 °F (>40.0 °C) or any Grade 4 prompted systemic event.
h. Designated site staff will review e-diary data online at frequent intervals (daily is optimal) for the 10 days following vacc ination to evaluate subject 
compliance and as part of the ongoing safety review and will collect the e-diary at Visit 2
i. Adverse events include nonserious adverse events, serious adverse events, and newly diagnosed chronic medical conditions.
j. A newly diagnosed chronic medical condition is defined as a disease or medical condition, not previously identified, that is expected to be persistent or 
otherwise long-lasting in its effects.C
CI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 151.INTRODUCTION
1.1.Indication
20-valent pneumococcal conjugate vaccine (20vPnC) is being developed for: 
Active immunization to prevent disease caused by  the Streptococcus pneumoniae
seroty pes in the vaccine.
1.2.Background and Rationale
1.2.1. Pneumococcal Disease
S pneumoniae are gram -positive encapsulated cocci that 
have been a leading cause of 
bacter emia, bacterial meningitis, pneumonia, and acute otitis media (AOM) and continue to 
be a major global public health concern.1,2,3  Serious pneumococcal disease may  occur at any  
age; however, children <5 years and adults  65 years of age are at particularly  increased 
risk.4  Individuals with certain comor bidities and immunocompromising conditions are also 
at risk.  
The annual burden of pneumococcal disease in children and adults in the United 
States has been estimated, using 2004 healthcare utilization and disease data. There were
approximatel y 445,000 hospitalizations, 2. 3million hospital days, 5.0 million outpatient
visits, and 22,000 annual deaths, including 19,000 from pneumonia annually, with the
majority  of the deaths ( 18,000) having occurred in persons 65 years of age.3These data 
represent disease burden after a relativel y short period of Prevnar(7-valent pneumococcal 
conjugate vaccine) use in the infant vaccine schedul e (<5 years). A preliminary  update of 
estimates in adults after introduction of Prevnar 13(13-valent pneumococcal conjugate 
vaccine [13vPnC]) suggests that although there has been a reduction in disease burden, 
207,000 hospitalizations for pneumococcal pneumonia ,meningitis , and sepsis (plausibility  
range of 106,000 -308,000) and 283,000 cases of pneumococcal disease (plausibility  range of 
145,000- 422,000) occurred in US adults in 2015.5Surveillance studies conducted in 
2010- 2012 by  the Centers for Dise ase Control and Prevention (CDC )found that S 
pneumoniae 
remains among the most common pathogens identified in community -acquired 
pneumonia ( CAP ) requiring hospitalization in the United States in both children and adults.6,7
Bacteremic pneumococcal pneumonia (accounting for the majority of invasive pneumococcal 
disease [ IPD]in adults) is less common than nonbacteremic pneumococcal pneumonia (an 
estimated 3 or more cases of nonbacteremic pneumococcal pneumonia occur for every  1 case 
of bacteremic pneumonia) , but it is associated with significant morbidity  and mortality1in all 
age groups. The CDC estimated that in 2015 there were 29,500 cases and 3350 deaths due to 
IPD in the United States.8In man y regions of t he world the disease burden is much higher, 
reflected in an assessment by  the World Health Organization (WHO) in 2008 estimating that 
1.6 million people die from pneumococcal disease each year.9  As these numbers suggest, 
Spneumoniae remains an important cause of serious disease in the United States and 
worldwide.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 16The poly saccharide capsule has been identified as an important virulence factor for this 
pathogen.  While more than 95 pneumococcal seroty pes differentiated by  their capsular 
polysaccharide compo sition have been identified ,only a subset of serot ypes are more 
commonly  associated with severe disease.10,11  Anticapsular antibodies directed against the 
specific seroty pe bind to the capsule and promote complement -mediated opsonophagocy tic 
killing and cl earance of the organism.12  Pneumococcal disease can be prevented with 
polysaccharide -based vaccines that induce antibody  responses with functional 
(opsonophagocy tic) activity  and target the capsular serot ypes responsible for disease.13
1.2.2. Vaccines to Prevent P neumococcal Disease
1.2.2.1. Pneumococcal Polysaccharide Vaccines
Vaccines containing free poly saccharides have been licensed since the 1970s.  One such 
vaccine, the 23 -valent pneumococcal poly saccharide vaccine (PPSV23), has been licensed in 
the United States sinc e 1983.14
,15  PPSV23 contains capsular pol ysaccharides for 23 
seroty pes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 
22F, 23F, and 33F).  PPSV23 elicits a T -cell–independent immune response.  Unconjugate d 
polysaccharide 
vaccines do not induce robust responses in certain pop ulations
(eg,immunocompromised persons, children <2 years of age, and adults  65 years of age), 
nor do they  generate immunologic memory , so their protective effect wanes over 2 to 
5years.4,15,16,17Moreover, their ability  to prevent nonbacteremic pneumonia, CAP, AOM, 
and nasophary
ngeal carriage is limited or lacking.13,17,18,19,20  Another limitation is that in 
several studies, individuals vaccinated with pneumococcal poly saccharide vaccine had lower 
functional antibody  responses following subsequent vaccination with either another dose of
pneumococcal poly saccharide vaccine or a dose of pneumococcal conjugate vaccine,
compared to the first dose of poly saccharide vaccine.21,22
,23Such “hy poresponsiveness ”
hasbeen observed with other poly saccharide vaccines as well, and raises co ncern regarding 
thequality  of response after revaccination or natural exposure to an invading vaccine -type 
(VT) pneumococcus.24Despite these limitations, a number of national vaccine policy  expert
bodies recommend PPSV23 vaccination of adults 65 years of age and/or in persons with
substantial risk factors for pneumococcal disease, to provide some degree of protection
against I PD due to serot ypes not covered b y existing pneumococcal conjugate vaccines.25
However, in the United States, the Advisory  Committee on I mmunization Practices (AC IP)
recommends that adults 65 years of age, or those with certain immunocompromising
conditions, receive 1 3vPnC first, followed by  PPSV23 1 year later. Other countries have
similar recommendations for certain risk groups. In contrast, because of concerns of
hyporesponsiveness, as well as other factors, most recommendations restrict PPSV23 to a
single lifetime dose in adults  65 years of age and 1 to 2 doses in most other high -
risk
populations.25,26,27

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 171.2.2.2. Pneumococcal Polysaccharide Conjugate Vaccines
Pneumococcal conjugate vaccines contain poly saccharides that are covalently  linked 
(conjugated) to an immunogenic protein.  This modification results in T -cell–dependent 
immune responses , which have been shown to be protective in y oung children, older adults, 
and populations with high -risk conditions.16,28  Prevnar wasthe first pneumococcal conjugate 
vaccine to be licensed (2000) and was indic ated for prevention of pneumococcal disease in 
infants and young children on the basis of efficacy studies.  Prevnar contained capsular 
polysaccharide conjugates for 7 pneumococcal seroty pes ( 4, 6B, 9V, 14, 18C, 19F, and 23F), 
each covalentl y linked to cross-reactive material 197 ( CRM 197), a nontoxic variant of 
diphtheria toxin.  These 7 seroty pes were responsible for approximatel y 80% to 90% of IPD 
in children <5 years of age in the United States and approximatel y 60% to 80% of IPD in the 
same age group in Europe at that time (1998- 2000).29
,30,31,32,33  These serot ypes also 
accounted for a high proportion of antibiotic- resistant strains.34  Prevnar demonstrated 
efficacy  against VT I PD, pneumonia, and AOM in large randomized controlled efficacy  
studies in infants.35
,36  The Prevnar components contained in a related pneumococcal 
conjugate vaccine also were demonstrated to be efficacious against 
clinically /radiographically  defined pneumonia.37
,38,39
,40  Following introduction of Prevnar, 
reduction of nasophary ngeal carriage and transmission has resulted in indirect herd effects, 
with a 92% reduction of Prevnar VT IPDin older adults 65 years of age.41,42
Prevnar 13 was developed to expand serot
ype coverage and was licensed in the United States 
in 2010.  Prevnar 13 includes t he same S pneumoniae serot ypes as Prevnar and an additional 
6 poly saccharide conjugates for serot ypes 1, 3, 5, 6A, 7F, and 19A.28,32,43  The vaccine was 
licensed for use in infants and y oung children based on comparisons of seroty pe-specific 
immunoglobulin G ( IgG
)to Prevnar, with supportive data to demonstrate the functional 
activity  of the immune responses.  Prevnar 13 was later licensed in adults based on an 
accele rated approval pathway  demonstrating comparable serot ype-specific opsonophagocy tic
activity (OPA) responses to PPSV23, followed by  traditional approval based on 
demonstration of efficacy against VT CAP44in CAPiTA (Community -Acquired Pneumonia 
Immunization Trial in Adults) ,a randomized controlled study  of adults 65 y ears of age and 
older.  Prevention of nonbacteremic VT CAP in this older adult population was also 
demonstrated and protection was observed through 4 y ears of follow -up.  This is notable 
given t he lack of definitive data showing that PPSV23 prevents nonbacteremic disease in 
older adults, and evidence that protection against IPD wanes significantl y over time.15  
Prevnar 13 has replaced Prevnar and is l icensed in the United States and many  other 
countries, with national recommendations for use in children and older adults.45,46,47,48  It has 
also been prequalified b y WHO for use in national infant immunization programs in lower -
and middle -income countries.49,50  Surveillance data from several countries following 
introduction of Prevnar 13 into the routine infant immunization program have demonstrated 
vaccine effectiveness against VT I PD in the vaccinated population.51,52,53

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 18Prevnar 13 was licensed for adults 50 years of age in 2011, and recommended by  theACIP 
for use in adults wit h immunocompromising conditions in 2012. In July  2016, it was also 
licensed for use in adults 18 to 49 y earsof age . The potential burden of VT CAP in adults in
the United States was demonstrated by  a study  conducted well after the introduction of
Prevnar into the routine infant immunization schedule, suggesting potential value in direct
immunization of adults rather than reliance solely on the herd effect.54The data on disease
burden , combined with the results of the CAPiTA study , led to the August 2014 ACI P
recommendation for all adults aged 65 years to receive Prevnar 13, followed by  PPSV23 six 
totwelve months later (except for those who had alread y received PPSV23 and for whom an
additional dose was not indicated ).In 2015, a 12-month interval between vaccinations was 
recommended, based on demonstrated higher frequency  of local reactions with short 
intervals, and theoretical immunogenicity considerations.27,55The recommendation for 
Prevnar 13 was made based on the potential added benefit in protecting against disease, 
particularl y nonbacteremic pneumonia caused b y the vaccine serot ypes. The continued 
recommendation for PPSV23 was in tended to provide expanded protection against I PD for 
seroty pes not in Prevnar 13. However, the prevalence of IPD due to most of the serot ypes 
contained onl y in PPSV23 has remained stable or slightly increased over the past 15 y ears, 
despite continued rec ommendation and use of PPSV23 in adults  65 years of age and 
high-risk adults.56,57
,58The continued presence of IPD due to serot ypes contained only  in
PPSV23 is likely  due to a combination of intrinsic population factors including age and
comorbidities, lim itations in the ability  of PPSV23 to prevent disease and reduce carriage,
limited duration of PPSV23 protection, and lack of boosting with subsequent doses, which
highlights the need for a better vaccine than PPSV23 and expanded coverage.
1.2.2.3. Rationale for 20v PnC
Because of the number of serot ypes that may cause pneumococcal disease among different 
geographic regions, different age populations, and different environmental backgrounds, 
there remains value in expanding serot ype coverage .
20vPnC is being develope d to further expand protection against the global burden of 
vaccine -preventable pneumococcal disease in children and adults over that of Prevnar 13. 
20vPnC contains the seroty pes present in Prevnar 13 plus 7 new serot ypes (8, 10A, 11A, 
12F, 15B, 22F, and 33F), as well as the same excipients as the currently licensed conjugate 
vaccine.  The pol ysaccharides of the 20 capsular seroty pes of S pneumoniae are each 
covalentl y linked to CRM 197.  These 7 additional serotypes were selected based on their 
relative pr evalence as a cause of IPD, their generalized geographic distribution, and other 
factors that would support inclusion, such as the presence of antibiotic resistance and greater 
disease severity  (eg, meningitis, mortality ).59,60,61,62,63,64,65,66,67,68,69,70These 7 s erotypes are 
also present in PPSV23.71Adding these additional serotypes to the 13 serot ypes in Prevnar 
13 is anticipated to further reduce the global burden of pneumococcal disease and provide 
protection comparable to, or greater than, that of PPSV23. 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 19The 20vPnC candidate is modeled after Prevnar and Prevnar 13, and contains 
polysaccharides of capsular serotypes of S pneumoniae , each covalently linked to CRM 197. 
 
 
 
 
A Phase 1 study is being conducted in healthy adults 18 to 49 years of age to support further 
development of 20vPnC. The details of this study can be found in the IB. 
The purpose of this study is to assess the safety, tolerability, and immunogenicity of 20vPnC 
in adults 60 to 64 years of age and to generate a safety and immunogenicity data set with 20vPnC to support and inform the design of the Phase 3 clinical development program for adults. The targeted age of the population for this study, adults 60 through 64 years of age, 
has been selected as this approximates the population ( ≥65 years of age) who are 
recommended for vaccination with 13vPnC and PPSV23 by ACIP, but are unlikely to have 
already received a pneumococcal vaccine. All subjects will receive either 20vPnC or 13vPnC for the initial vaccination. 13vPnC will serve as a reference vaccine for safety and tolerability assessments and for immunogenicity of the 13 common serotypes in 20vPnC. At the second vaccination, 1 month later, the 20vPnC recipients will receive saline and the 13vPnC recipients will receive PPSV23. PPSV23 will provide a reference for the immune responses to the 7 additional serotypes in the 20vPnC. Subjects will also return 12 months after Vaccination 1 for measurement of circulating antibodies at that time.
Additional information for this compound may be found in the single reference safety 
document (SRSD), which for this study is the 20vPnC IB. The SRSD for 13vPnC and PPSV23 are the US package inserts (USPIs).
2. STUDY OBJECTIVES AND ENDPOINTS
2.1. Primary Objective and Endpoints2.1.1. Primary Objective
•To describe the safety profile of 20vPnC in the study population.
2.1.2. Primary Endpoints
•Proportions of subjects reporting prompted local reactions within 10 days after 
vaccination (redness, swelling, and pain at the injection site).
•Proportions of subjects reporting prompted systemic events within 7 days after 
vaccination (fever, headache, fatigue, muscle pain, and joint pain).CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 20•Proportions of subjects reporting adverse events (AEs) within 1 month after vaccination.
•Proportions of subjects reporting serious adverse events (SAEs) and newly diagnosed 
chronic medical conditions (NDCMCs) within 6 months and 12 months after vaccination.
2.2. Secondary Objective and Endpoints
2.2.1. Secondary Objective
•To describe the immunogenicity of 20vPnC in the study population.
2.2.2. Secondary Endpoints
•Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers 
(GMTs) 1 month after vaccination.
•Pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs) from before 
vaccination to 1 month after vaccination.
3. STUDY DESIGN
This will be a Phase 2, multicenter, randomized, active-controlled, double-blind study with a 
2-arm parallel design, conducted at investigative sites in the United States.  A total of 440 
adults 60 through 64 years of age with no history of pneumococcal vaccination will be enrolled and randomized equally to receive an initial vaccination with either:
oa single dose of 20vPnC followed 1 month later by saline (placebo) administration in 
the active vaccine group (20vPnC/saline group), or 
oa single dose of 13vPnC followed 1 month later by a dose of PPSV23 in the control 
group (13vPnC/PPSV23 group).  
13vPnC will serve as a control for safety, as well as immunogenicity of the 13 serotypes in 
common with 20vPnC. PPSV23 will serve as a control for immunogenicity of the 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) in 20vPnC as described in Table 1 .CCI
CCICCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 21Table 1. Time Points for Key Safety and Immunogenicity Objectives by 
Investigational Product
20vPnC Control –13vPnCaControl –PPSV23b
Prom pted local reactions X
(10 days after Visit 1)X
(10 days after Visit 1)
Prom pted systemic 
eventsX
(7 days after Visit 1)X
(7 days after Visit 1)
Adverse events c X
(1 month after Visits 1 
and 2)X
(1 month after Visit 1)X
(1 month after Visit 2)
Immune responses to 
serotypes in common 
with 13vPnC: 1, 3, 4, 5, 
6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, 23FX
(1 month after Visit 1)X
(1 month after Visit 1)
Immune responses to 
additional 7 serotypes: 8, 
10A, 11A, 12F, 15B, 
22F, 33FX
(1 month after Visit 1)X
(1 month after Visit 2)
a.Control group from enrollment and vaccination with 13vPnC at Visit 1 until vaccination with PPSV23 at 
Visit 2.
b.Control group after vaccination wit h PPSV23 at Visit 2 .
c.SAEs and newly diagnosed chronic medical conditions ( NDCMCs )will be collected through Visit 5 
(12months after Visit 1) .
On Day  1 (Visit 1), subjects will have blood drawn for immunogenicity  assessments, receive 
an investigational product (20vPnC or 13vPnC ;the investigational products have the same 
appearance and can be administered by  unblinded or blinded site staff), be observed for 
30 minutes after vaccination, an d receive safet y follow -up and electronic diary  (e-diary ) 
instructions.  L ocal reactions (pain, redness, and swelling) at the injection site will be 
prompted for and collected daily  in an e -diary  from Day  1 through Day 10 after the Visit 1 
vaccination.  S ystemic events (fever, fatigue, headache, muscle pain, and joint pain) 
and use 
of antipy retic medications will be prompted for and collected daily in an e -diary  from Day  1 
through Day 7 after the Visit 1 vaccination.  AEs (including nonserious AEs, SAEs, an d 
NDCMCs) will be assessed for approximatel y 1 month after the Visit 1 vaccination (through 
Visit 2). Refer to Section 8.1.4 for the definition of a
nNDCMC.
At Visit 2 (28 -35 day s after Visit 1), subjects will return for follow -up.  Information will be 
collected from the subjects on AEs and e -diary  follow -up (as needed), blood will be drawn 
for immunogenicity  assessments (this represents the 1 -month post –Vaccination 1 time point) , 
a dose of sa line will be administered to subjects who received 20vPnC at Visit 1, and 
PPSV23 will be administered to subjects who received 13vPnC at Visit 1.  The subjects will 
be observed for 30 minutes and will receive safet y follow -up instructions.  The 
investigati
onal product will be prepared at this visit by  a designated unblinded site staff 
member .  AEs (including nonserious AEs, SAEs, and NDCMCs) will be assessed for 
approximatel y 1 month after the Visit 2 vaccination (through Visit 3).

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 22At Visit 3 (28-35 days after Visit 2), subjects will return for safety follow-up and a blood 
draw for immunogenicity assessments.
At Visit 4 (approximately 6 months after the first vaccination), the sites will contact the 
subject via telephone to inquire about SAEs and NDCMCs.
At Visit 5 (12 months [350 to 378 days] after the first vaccination), subjects will return to 
have a blood draw for immunogenicity assessments.  SAEs and NDCMCs will also be collected at this visit.
 
 
 
 
 
 
 
 
3.1. Duration of Subject Participation
Each subject will participate in the study for approximately 12 months. 
3.2. Duration of Study
The study duration will be approximately 16 months.
3.3. Number of Subjects
Approximately 440 subjects (220 per group) will be randomized for a total of approximately 
400 evaluable subjects (assuming a 10% dropout rate).  Subjects who withdraw or are withdrawn from the study after randomization will not be replaced, regardless of the reason for withdrawal. 
4. SUBJECT ELIGIBILITY CRITERIA
This study can fulfill its objectives only if appropriate subjects are enrolled.  The following 
eligibility criteria are designed to select subjects for whom participation in the study is considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.
Subject eligibility should be reviewed and documented by an appropriate member of the 
investigator’s study team before subjects are included in the study.CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 234.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the study .
2.Willing and able to comply  with scheduled visits, treatment plan, laboratory tests, and 
other study  procedures including completion of the e-diary .
3.Expected to be available for the duration of the study  and can be contacted by  telephone 
during study  participation.
4.Male or female adults 60 to 64years of age (from the 60 thbirthday  up to ,but not 
including, the 65th birthday ) at enrollment.
5.Health y adults, including adults with preexisting stable disease, defined as disease not 
requiring significant change in therap y or requiring hospitalization within 3 months 
before receipt of investigational product, as determined by  medical history, phy sical 
examination, laboratory screening, and clinical judgment of the investigator. 
6. F emale subjects who are not of 
childbearing potential must (ie, meet at least 1 of the 
following criteria ):
a.Have a chieved postmenopausal status, defined as follows: cessation of regular 
menses for at least 12 consecutive months with no alternative pathological or 
physiological cause; status may  be confirmed by  having a serum follicle -stimulating 
hormone (FSH) level confirming the postmenopausal state;
b. Have undergone a docum ented hy sterectomy  and/or bilateral oophorectomy ; 
c.Have medically  confirmed ovarian failure. 
All other female subjects (including female subject s with tubal ligations) are considered to be 
of childbearing potential. 
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1. Investigat or site staff members directl y involved in the conduct of the study  and their 
family  members, site staff members otherwise supervised by  the i
nvestigator, or subjects 
who are Pfizer emplo yees, including their family  members, directl y involved in the 
conduct of the study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 242. Participation in other studies involving investigational drug(s) , investigational vaccines, 
or investigational devices within 28 day sprior to study  entryand/or during study  
participation. Participation in purely  observational studies is acceptable.
3.Serious chronic disorder including metastatic malignancy , severe chronic obstructive 
pulmonary  disease (COPD) requiring supplemental oxy gen, end- stage renal disease with 
or without dialy sis, clinically  unstable cardiac disease, or an y other disorder that, in the 
investigator’s opinion, excludes the subject from participating in the study .
4.Other acute or chronic medical or ps ychiatric condition including recen t (within the past 
year) or active suicidal ideation or behavior or laboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administration or 
may interfere with the interpretation of study  results an d, in the judgment of the 
investigator, would make the subject inappropriate for entry  into this study .
5.Previous vaccination with any  licensed or investigational pneumococcal vaccine, or 
planned receipt through study  participation.
6.History  of severe advers e reaction associated with a vaccine and/or severe allergic 
reaction (eg, anaph ylaxis) to any  component of 13vPnC, 20vPnC, or PPSV23.
7.History  of microbiologically proven invasive disease caused by  Spneumoniae .
8.Subjects who receive treatment with immunosuppressive therap y, including cytotoxic 
agents or s ystemic corticosteroids, or planned receipt through the last postvaccination 
blood draw. If systemic corticosteroids have been administered short term (<14 day s) for 
treatment of an acute illness, subjects should not be enrolled into the study  until 
corticosteroid therap y has b een discontinued for at least 28 days before investigational 
product 
administration. Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or 
eyes) corticosteroids are per mitted.
9. Subjects with known or suspected immunodeficiency  or other conditions associated with 
immunosuppression, including, but not limited to, immunoglobulin class/subclass 
deficiencies, generalized malignancy , human immunodeficiency  virus (HIV) infection, 
leukemia, ly mphoma, or organ or bone marrow transplant.  
10. Bleeding diathesis or condition associated with prolonged bleeding that would in the 
opinion of the investigator contraindicate intramuscular injection.
11.Receipt of blood/plasma products or immunog lobulin, from 60 day s before 
investigational product administration, or planned receipt through stud y participation.
12.Pregnant female subjects ;breastfeeding female subject s;female subjects of childbearing 
potential and fertile 
malesubjects with partners of childbearing potential who are , in the 
opinion of the investigator, sexuall y active and at risk of pregnancy with their partners 
and are unwilling or unable to use a highly  effective method of contraception as outlined 
in this protocol for at least 28 day s after the last dose of investigational product.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 254.3.Temporary Delay Criteria
The following conditions are temporary  or self -limiting and a subject may be vaccinated 
and/or have blood drawn in the study  once the condition(s) has/have resolved and no other 
exclusion criteria are met. The blood draws prior to V accinations 1 and 2 and the respective 
vaccinations should take place on the s ame day  (Visit 1 and Visit 2). 
4.3.1. Criteria for Temporarily Delaying Vaccine Administration (Visits 1 and 2)
Febrile illness ( oral temperature 100.4 F [38C]) or other acute illness within 48 hours 
before investigational product administration.
Receipt of an y inactivated vaccine within 14 days orany live vaccine within 28 days 
before investigational product administration.
Rece ipt of short- term (<14 day s) systemic corticosteroids. Investigational product 
administration should be delay ed until sy stemic corticosteroid use has been d iscontinued 
for at least 28 days. Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.
4.3.2.
Criteria for Temporarily Delaying Blood Draw (Visits 1, 2, 3, and 5)
Receipt of antibiotic therapy  within 72 hours before blood draw.
4.4.Lifestyle Requirements 
4.4.1. Contraception
All male subjects who areable to father ch ildren and who are , in the opinion of the 
investigator, sexually  active and at risk for pregnancy  with their partner(s) must agree to use 
a highly  effective method of contraception consistently  and correctl y for at least 28 days after 
the last dose of inve stigational product.  The investigator or his or her designee , in 
consultation with the subject, will confirm that the subject has selected anappropriate 
method of contraception for the individual subject and his partner from the permitted list of 
contrac eption methods (see below) and will confirm that the subject has been instructed in its 
consistent and correct use.  A t time points indicated in the Schedule of Activities, the 
investigator or designee will inform the subject of the need to use highl y effe ctive 
contraception consistently and correctl y and document theconversation and the subject’s 
affirmation in the subject’s chart (subject sneeds to affirm their or their partners consistent 
and correct use of at least 1 of the selected methods of contrace ption) .  In addition, the 
investigator or designee will instruct the subject to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject ’s
partner .
Highly  effective methods of contraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie,perfect use) and 
include the following
:

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 261.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) ,provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the entire 
study  and has been using that hormonal contraceptive for an adequate period of time to 
ensure effectiveness.
2.Correctl y placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WI TH a separate spermicide product (ie,foam, gel, 
film, cream, or suppository ). For countries where spermicide is not availa ble or condom 
plus spermicide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilization with absence of sperm in the postvasectomy  ejaculate .
5.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal oc clusive procedure 
(provided that occlusion has been confirmed in accord ance with the device’s label).
6. Female partner who meets the criteria for nonchildbearing potential, as described below:
Achieved postmenopausal status, defined as follows: cessation of regular menses for 
at least 12 consecutive months with no alternative pathological or ph ysiological 
cause; status may  be confirmed by  having an FSH level confirming the 
postmenopausal state;
Have undergone a documented hy sterectomy  and/or bilateral oophore ctomy ;
Have medically  confirmed ovarian failure .
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
All sexually  active male subjects must agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate b y using a condom consistently  and c orrectl y, beginning 
with the first dose of investigational product and continuing for at least 28 days after the last 
dose of investigational product.
4.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriately  qualified m edical personnel for the 
study  is documented in the study  contact list located in thesupporting study  documentation .
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects are provided w ith a contact card.   The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 27event that the investigat or site staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga tor
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
number is not intended for use b
y the subject directly , and if a subj ect calls that number, he 
or she will be directed back to the investigator site.
5. INVESTIGATIONAL PRODUCTS
For the purposes of this study , and per International Co uncil for Harmoni sation ( ICH)
guidelines,
investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, wh en used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33) .
For this study , the investigational products are 20vPnC, 13vPnC, PPSV23 and saline .
5.1.Allocation to Investigational Product
Allocation of subj ects to vaccine groups will proceed through the use of an i nteractive 
response technology  (IRT) system ( interactive Web- based response [IWR]).  The site
personnel will be required to enter or select information including but not limited to the 
user’s ident ification (ID) and password, the protocol number ,and the subject number. The 
site personnel will then be provided with a randomization number and dispensable unit (DU) 
or container number when investigational product is being supplied via the IRT s ystem.  The 
IRT s ystem will provide a confirmation report containing the subject number, randomization 
number, and DU or container number assigned. The confirmation report must be retained in
the site files .
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system . 
5.2.Blinding of the Site Personnel
Site personnel taking part in any  subject randomization, assessments, interviews, data 
collection ,or case report form ( CRF )data entry
, including the investigator andinvestigator 
staff, will be blinded to investigational product assignments during the study . 
Vaccination 1 will be administered in a double -blind fashion asthe appearance of 20vPnC 
and 13vPnC are identical (prefilled s yringes packaged in blinded cartons) . 
Vaccination 2 will be prepared b y an unblinded site staff member . Vaccination 2 will be
administered to blinded subjects; the 2 investigational products will have an identical 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 28appearance after preparation. The study  staff administe ring the vaccine s can be blinded or
unblinded, but only the designated unblinded site staff member assigned to prepare 
Vaccination 2 will be unblinded (see Section 5.6.2 ).All other study  personnel including the 
principal investigator (PI), and the subject, will be blinded.  The PI  will assign the 
responsibility  of preparing Vaccination 2 to unblinded persons who will not participate in the 
evaluation of an y stud y subject.  More than 1 unblinded site staff member may be assigned.  
A member of the stud y site staff or clinic pharmacy should fulfill this role.  Contact between 
the unblinded staff member who will prepare Vaccination 2 and study  subject s should be 
kept to a minimum.
The investigator , study  coordinator, and any  site staff other than the unblinded site staff 
member must not be allowed to know the investigational product assigned to any  study  
subject and must not be allowed to see the inner packaging containing the investigational 
produ ct.The outer investigational product cartons will be blinded.
5.3.Blinding of the Sponsor
Sponsor personnel directly involved in evaluating subject data will be blinded to vaccine
assignment until the analysis of all available data through Visit 2 is availab le, following the 
principles outlined in I CH E9 guideline on Statistical Principles for Clinical Trials. A data 
blinding plan will be created to describe the blinding requirements and unblinding events.  
The plan to control distribution of unblinded data among designated Pfizer personnel and 
core stud y team members will be specified in the data dissemination plan.  Laboratory 
personnel performing the immunologic assay s will be blinded until the database has been 
locked and unblinded.
5.4.Breaking the Blind 
The study  will be subject and investigator blinded.
At the initiation of the study , the 
investigator site will be instructed on the method for 
breaking the blind for an individual subject .  The method will be an electronic process.  
Blinding codes should be broken only in exceptional circumstances when knowledge of the 
actual treatment code is absolutely  essential for further management of the subject.
Investigators are encouraged to discuss with a member of the stud y team if they believe that 
unblinding is necessary . When the blinding code is broken, the reason must be fully  
documented and entered on the CRF .
5.5.Subject 
Compliance
All doses of investigational product will be administered by  the appropriately  designated 
study  staff at the investigat orsite.
5.6.Investigational Product Supplies
20vPnC, 13vPnC, PPSV2 3, and saline will be provided by  the sponsor to the study  sites.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 29Study vaccines will be packed and labeled as investigational product in accordance with 
current guidelines and applicable local and legal regulatory requirements.  The formulation of the investigational products is described below.
5.6.1. Dosage Form(s) and Packaging
20vPnC contains saccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 
10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F individually conjugated to 
CRM
197.   
 
 
 
 
20vPnC and 13vPnC will be supplied to the site as packaged, single-use prefilled syringes 
and labeled according to local regulatory requirements.
PPSV23 is a licensed commercial product (Pneumovax, Merck) and is a clear, sterile solution 
consisting of a mixture of purified capsular polysaccharides from 23 types of S pneumoniae : 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 
and 33F. The vaccine is formulated to contain 25 μg of each of the 23 purified
polysaccharide serotypes per 0.5-mL dose of vaccine in an isotonic saline solution containing 
0.25% phenol as a preservative. PPSV23 will be supplied by the sponsor to the site as packaged vials and labeled according to local regulatory requirements.
The placebo will consist of a sterile normal saline solution for injection (0.9% sodium 
chloride injection) and will be supplied to the site as packaged vials and labeled according to local regulatory requirements.
5.6.2. Preparation and Dispensing
See the Investigational Product Manual (IP manual) or package insert for instructions on how 
to prepare the investigational product for administration.  Investigational product should be prepared and dispensed by an appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance.  CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 30Investigational product will be prepared by qualified site personnel according to the IP
manual. The investigational product will be administered to blinded subjects.
5.7. Administration
All subjects will receive a single dose (0.5 mL) of investigational product administered 
intramuscularly into the deltoid muscle, preferably in the nondominant arm, at Visit 1 and Visit 2.
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute hypersensitivity reaction should be available in accordance with local guidelines for standard immunization practices.
Administration of investigational products should be performed by an appropriately 
qualified, Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by local, state, and institutional guidance. 
Investigational product administration details will be recorded on the CRF.
5.8. Investigational Product Storage 
The investigator or an approved representative, eg, pharmacist, unblinded 
dispenser/administrator, will ensure that all investigational products, including any comparator and/or marketed products, are stored in a secured area with controlled access under required storage conditions and in accordance with applicable regulatory requirements.
Investigational products should be stored in their original containers and in accordance with 
the labels.
20vPnC, 13vPnC, PPSV23, and saline will be shipped to the study site after required 
regulatory and legal documents have been received by the sponsor.
 
 
 
Any storage conditions stated in the SRSD (20vPnC IB, 13vPnC USPI, and PPSV23 USPI)
will be superseded by the storage conditions stated on the product label.
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as applicable, including frozen, refrigerated, and/or room-temperature products).  This should be captured from the time of investigational product receipt throughout the study.  Even for continuous-monitoring systems, a log or site procedure that ensures active evaluation for excursions should be available.  The intent is to ensure that the minimum and maximum 
temperature is checked each business day to confirm that no excursion occurred since the last CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 31evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all nonworking day s upon return to normal operations.  The operation of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they are maintained in working order.
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery . The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling , as soon a s possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer .
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out of thetemperature range described in the labeling are not 
considered excursions.
5.9. Investigational Product Accountability 
The unblinded dispenser/administrator at the investiga torsite must maintain adequate records 
documenting the receipt, use, loss, or othe r disposition of the investigational product 
supplies.  All investigational products will be accounted for using a drug accountability  
form/record .
Used needles and s yringes should be disposed of according to local practice.  Empty outer 
investigational pr oduct containers must be retained until reviewed by  the sponsor's unblinded 
site staff and then may  be destroy ed after the sponsor’s unblinded site staff has performed 
accountability .  Investigational product return/destruction must be documented on the 
accountability  log.
5.9.1. Destruction of Investigational Product Supplies 
The sponsor or designee will provide guidance on the destruction of un used investigational 
product (eg, at the site). If destruction is authorized to take place at the investigator site, t he 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer ,and all destruction must be adequatel y documented.
5.10. Concomitant Trea tment(s)
5.10.1. Prohibited During the Study
Receipt of an y investigational vaccines, drugs, or medical devices isprohibited 
during subject participation in the study .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 32Receipt of an y nonstud y pneumococcal vaccine is prohibited during subject 
participation in the study .
Receipt of an y licensed vaccine, with the exception of licensed inactivated influenza 
vaccine, is prohibited from Visit 1 to Visit 4 (6 months after Vaccination 1).
Receipt of blood/plasma products, immunoglobulins, and/or immunosuppressive 
therap y(including a 14-day course of s ystemic corticosteroids) is prohibited during 
subject participation in the study .  
5.10.2. Permitted During the Study
Licensed inactivated influenza vaccine may  be given >14 day s prior to or >14 day s 
after investigational vaccine administration (Visit 1 and Visit 2). If medically  
necessary  (eg, pandemic), influenza vaccine may  be given at an y time.
Prescription and nonprescription medications, vitamins, minerals, and herbal 
remedies are permitted during subject participation in th e study .
The use of proph ylactic antipy retic medication, while permitted, is not recommended 
on the day  prior to vaccination or the day  of investigational product administration.
Inhaled/nebulized, topical (skin, ey es or ears), or localized injections of 
corticosteroids (eg, intra- articular or intrabursal administration) are permitted during 
subject participation in the study .
5.10.3. Recording Concomitant Treatments
The name and date of administration for all nonstudy  vaccinations received from the time of 
signing of the informed consent document to Visit 5 will be collected and recorded in the 
CRF (per Section 5.10.1 and Section 5.10.2 ).
Medications taken to treat SAEs or NDCMCs from the time of signing of the informed 
consent document to Visit 5 will be recorded in the CRF.
6.
STUDY PROCEDURES 
The study  procedures are summarized in the Schedule of Activities .  The day  of vaccination 
is considered to be Day  1.
6.1.Visit 1 (Vaccination 1 – Day 1)
Prior to vaccination:
Obtain written informed consent before performing any  study -specific procedures. 
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary  delay  criteria are met.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 33Assign a subject number via the I RT.
Obtain and record the subject demograph y (sex, birth date, ethnicity, race, racial 
designation).
Assess and record tobacco usage.
Obtain and record the medical history  including the presence of chronic conditions
(eg,diabetes, h ypertension, atherosclerosis, COPD) and/or medical history  of 
significance such as relevant surgical procedures).  
Perform ph ysical examination evaluating an y clinically  significant abnormalities within 
the following body  systems: general appearance; skin; head, ey es, ears, nose, and throat; 
heart; lungs; abdomen; musculoskeletal; extremities; neurological; and l ymph nodes.  
Abnormal results will be recorded in the CRF. 
Measure and record the subject’s height, weight, and oral temperature ( F/C).
Record nonstud y vaccinations and medications as described in Section 5.10.3 .
Assign a randomization number and an investigational product container number via the 
IRT.  This must be the la st step before proceeding.  A blinded or unblinded site staff 
member will prepare the investigational product according to the IPmanual.
After randomization:
Collect a blood sample of approximatel y 30 mL for immunogenicity  assessments prior to 
vaccination. 
The b linded/u nblinded dispenser/administrator will a
dminister a single 0.5- mL injection 
of investigational product into the deltoid muscle (preferabl y in the nondominant a rm). 
Blinded site staff will observe the subject for at least 30 minutes after investigational 
product administration for an y acute reactions.  Record an y acute reactions on the AE 
CRF and on an SAE form as applicable.
Issue the subject a measuring device to measure injection site reactions and a digital 
thermometer and provide instructions on their use .
Issue the subject an e -diary  and provide instructions on its use and completion.  Ask the 
subject to complete the e -diary  from Day 1 to Day 10, with Day 1being the day  of 
vaccination.
Ask the subject to contact the investigator site staff or investigator immediately  during 
the 10- day postvaccination period if he or she experiences redness or swelling at the 
injection site measuring 21measuring device uni ts (10.5 cm), severe injection site pain 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 34(prevents dail y activity ),a fever of >104 F, or an y Grade 4 prompted s ystemic event to 
determine if the event requires further assessment by  the investigator.
Ask the subject to contact the investigator or investigator site staff immediately  if an y 
significant illness or medical event (eg, emergency room visit or hospitalization) occurs 
during the study  period.
Remind the subject to use appropriate contraceptives until 28 day s after vaccination, if 
applicable ,and document the conversation and the subject’s affirmation in the subject’s 
chart .
Record AEs , SAEs, andNDCMCs as described in 
Section 8.
The investigator or an authorized designee completes the CRF and updates the 
investigational product accountability  records.
The investigator or appropriately  qualified designee reviews the e -diary  data online at 
frequent intervals (dail y is optimal) for the 10 days following vaccination to evaluate 
subject com pliance and as part of the ongoing safety  review.
6.2.Visit 2 (Vaccination 2 – 28 to 35 Days After Visit 1)
Prior to vaccination:
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary  delay criteria are met.
Measure and record the subject’s oral temperature ( F/C).
Record nonstud y vaccinations and medications as described in Section 5.10.3 .
Collect a blood sample of approxi matel y 50 mL for immunogenicity  assessments prior to 
vaccination. 
Review the subject’s e- diary  data and collect the e -diary . Collect stop dates of any  
e-diary  events ongoing on the last day  that the e -diary  was completed and record stop 
dates in the CRF.
Determine whether an y AEs, SAEs, or NDCMCs have occurred since Visit 1 and follow 
up on any  previousl y reported events to determine the outcome (ie, record stop dates or 
confirm if they  are still continuing) and record as described in Section 8
. 
An unblinded site staff member will prepare the investigational product according to the 
IPmanual.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 35After vaccination (including investigational product administration):
The b linded/u nblinded dispense r/administrator will administer a single 0.5 -mL injection 
of investigational product into the deltoid muscle (preferabl y in the nondominant arm). 
Blinded investigator site staff will observe the subject for at least 30 minutes after 
investigational produc t administration for any  acute reactions.  Record any  acute 
reactions on the AE CRF and on an SAE form as applicable.
Remind the subject to contact the investigator or investigator site staff immediatel y if an y 
significant illness or medical event (eg, eme rgency  room visit or hospitalization) occurs 
during the study  period.
Remind the subject to use appropriate contraceptives until 28 day s after vaccination, if 
applicable ,and document the conversation and the subject’s affirmation in the subject’s 
chart .
The investigator or an authorized designee completes the CRF.
6.3. Visit 3 (Follow- up Vaccination 2 – 28 to 35 Days After Visit 2)
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary  delay criteria are met.
Record nonstud y vaccinations and medications as described in Section 5.10.3 .
Perform a contraception check, if applicable ,and document the conversation and the 
subject’s affirmation in the subject’s chart.
Collect a blood sample of approximatel y 30 mL for immunogenicity  assessments. 
Determine whether an y AEs, SAEs, or NDCMCs have occurred since Visit 2and follow 
up on any  previousl y reported events to determine the outc ome (ie, record stop dates or 
confirm if they  are still continuing) and record as described in Section 8.
Remind the 
subject to contact the investigator or investigator site staff immediatel y if any 
significant illness or medical event (eg, emergency room visit or hospitalization) occurs 
during the study  period.
The investigator or an authorized designee completes the CRF.
6.4.Visit 4 (6-
Month Safety Collection by Telephone – 168 to 196 Days After Visit 1)
Record nonstud y vaccinations and medications as described in Section 5.10.3 .
Determine whether any SAEs or NDCMCs have occurred since Visit 3 and follow up on 
any previousl y reported events to determine the outcome (ie, record stop dates or confirm 
if they  are still continuing) and record as described in Section 8.  

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 36Remind the subject to contact the investigator or investigator site staff immediatel y if an y 
significant illness or medical event (eg, emergency room visit or hospitalization) occurs 
during the study  period.
The investigator or an authorized designee completes the CRF.
6.5.Visit 5 (Persistence Blood Draw and 12- Mon th Safety Collection – 350 to 378Days 
After Visit 1)
Ensure and document that all of the inclusion criteria and none of the exclusion criteria 
are met and that none of the temporary  delay  criteria are met.
Record nonstud y vaccinations and medications as d escribed in Section 
5.10.3 .
Determine whether any SAEs or NDCMCs have occurred since Visit 4 and follow up on 
any previousl y reported events to determine the outcome (ie, record stop dates or confirm 
if they  are still continuing) and record as described in Section 8.
Collect a blood sample of approximatel y 50 mL for immunogenicity  assessments. 
The investigator or an authorized des ignee completes the CRF.
6.6.Unscheduled Visits
If the subject reports redness or swelling at the injection site measuring 21measuring 
device units ( 10.5 cm) or severe injection site pain during the 10 -day post –Vaccination 1 
period, a telephone contact must occur as soon as possible between the investigator or 
medically  qualified designee and subject to assess if an unscheduled investigator site visit is 
required.  A n investigator site visit should be scheduled as soon as possible to assess the 
extent of the reaction unless any  of the following is true:
The subject is unable to attend the unscheduled visit.
The reaction is no longer present at the time of the telephone contact.
The subject recorded an incorrect value in the e
-diary  (confirmation of an e -diary data 
entry  error).
The PI  or authorized designee determined it was not needed.
This telephone contact will be recorded in the subject’s source documentation and the CRF.
If the subject is unable to attend the unscheduled visit, or the PI  or authorized de signee 
determined it was not needed, an y ongoing reactions must be assessed at Visit 2.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 37During the investigator site visit, the reactions should be assessed b y the investigator or a 
medically  qualified member of the study  staff such as a study  physician or a study  nurse, as 
applicable to the investigator’s local practice, who will:
Measure oral temperature ( F/C).
Measure minimum and maximum diameter sof redness (if present).
Measure minimum and maximum diameter sof swelling (if present).
Assess injection site pain (if present) in accordance with the grades provided in 
Section 7.1.2.1.
Assess for other findings associated with the reaction and record on the AE page of the 
CRF, if appropriate.
The investigator or an authorized designee will complete the unscheduled visit assessment 
page of the CRF.
Subjects will also be instructed to contact investigator site staff if they  experience a fever 
>104.0
F or an y possible Grade 4 prompted s ystemic even t (ie, emergency room visit or 
hospitalization for headache, fatigue, muscle pain, joint pain) within 7 days after vaccination.
Subjects will also be instructed to contact the investigator site to report an y significant 
illness, medical event, or hospitali zation that occurs during the study  period.  The 
investigator site should determine if an unscheduled visit to further evaluate the event is 
warranted in all such cases.
Additionally , study  staff may  contact the subject to obtain additional information on Grade 3 
events entered into the e- diary .
6.7.Subject Withdrawal
An investigator and/or sponsor can withdraw a subject from the stud y if deemed appropriate.  
In addition, if a subject fails to continue to meet the inclusion criteria, new information 
becomes av ailable that would exclude the subject, or the subject develops a condition or 
situation that would meet exclusion criteria, the subject may  be considered for withdrawal.
Reasons wh y a subject may discontinue or be withdrawn from the study include, but are not 
limited to, failure to meet entrance criteria (screening failure), AE, death, pregnancy, 
protocol deviation, lost to follow -up, no longer willing to participate in the study , study  
terminated b y the sponsor,  or an y other reason.  Subjects who have re ceived the 
investigational product will not be replaced regardless of the reason for withdrawal.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 38The investigator should capture the reason for withdrawal in the CRF for all subjects and a 
6-month post –Vaccination 1 follow -up telephone contact for the coll ection of safet y 
information should be completed for all subjects who have been withdrawn after 
administration of investigational product unless the subject has withdrawn consent for any  
future contact.
Subjects may withdraw from the study  at any  time at t heir own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also 
Withdrawal From the Study  Due to Adverse Events ,Section 8.1.3) or behavioral reasons, or 
the inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given investigator site. 
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject. All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record. In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The investigator s hould inquire 
about the reason for withdrawal, request that the subject return for a final visit, if applicable, 
and follow up with the subject regarding an y unresolved AEs.
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
Withdrawal of Consent :
Subjects who request to discontinue receipt of investigational product will remain in the 
study  and must continue to be followed for protocol specified follow- up procedures. The 
only exception to this is when a subject specifically  withdraws consent for any  further 
contact with himor her or persons previously  authorized by  
the subject to provide this 
information. Subjects should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of investigational product or also from study  procedures and/or 
posttreatment study  follow -up. In the event that vital status (whethe
r the subject is alive or 
dead) is being measured, publicly  available information should be used to determine vital 
status only  as appropriately  directed in accordance with local law.
Lost to f ollow -up: 
All reasonable efforts must be made to locate subjec ts to determine and report their ongoing
status. This includes follow- up with persons authorized by  the subject as noted above. Lost 
tofollow -up is defined by  the inabilit y to reach the subject after a minimum of 2documented 
phone calls, faxes, or emails as well as lack of response by  the subject to 1 registered mail 
letter. All attempts should be documented in the subject’s medical records. If it is 
determined that the subject has died, the investigator site may use locall y permissible 
methods to obt ain the date and cause of death. If the investigator’s use of a third
-party 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 39representative to assist in the follow- up portion of the study  has been included in the 
subject’s informed consent, then the investigator may  use a sponsor -retained third- party 
representative to assist investigator site staff with obtaining the subject’s contact information 
or other public vital status data necessary  to complete the follow -up portion of the study . 
The investigator site staff and representative may consult publicly available sources, such as 
public health registries and databases, in order to obtain updated contact information. If,
after all attempts, the subject remains lost to follow- up, then the last -known -alive date as 
determined b y the investigator should be r eported and documented in the subject’s medical 
records.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -
required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumsta nces outside of the control of the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be per formed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timel y manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .Serum samples should be processed an d stored as indicated in the 
study reference manual (SRM) or equivalent document .
7.1.Safety Parameters
Safety  parameters will be assessed as described in the Schedule of Activities, Section 6
, and 
below.
A medical history , phy sical examination, and measurement of oral temperature will be 
performed on all subjects prior to V accination 1to determine subject eligibility  and to 
establish a clinical baseline. Significan t medical history  and observations from the phy sical 
examination and temperature measurement will be documented and recorded in the CRF.
Acute reactions within the first 30 minutes after investigational product administration will 
be assessed and documented as an AE or SAE, as appropriate, in the CRF.
Prompted e -diary  events, including local reactions and sy stemic events that occur 10 and 
7days,respectively ,after investigational product administration at Visit 1, are graded as 
described in Section 7.1.2 .  In addition, AEs, SAEs, and NDCMCs will be collected as 
defined in Section 8.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 407.1.1. Subject Electronic Diary
The subject will be ask ed to monitor and record local reactions for 10 day s and sy stemic 
events and antip yretics/pain medication used to treat sy mptoms for 7 day s, each evening 
following V accination 1(Day  1 through Day  10 or Day  7,respectivel y, where Day  1 is the 
day of vaccin ation) on a sy stem that uses a personal digital assistant (PDA) or other 
technology .  This s ystem, hereafter referred to as the subject’s e -diary , allows recording of 
these assessments only within a fixed time window, thus providing the accurate 
representa tion of the subject’s experience at that time.  Data on local reactions, sy stemic 
events, and antipy retics/pain medication used to treat sy
mptoms reported in the e -diary  will 
be transferred electronically  to the e- diary  vendor, where they  will be available for review b y 
investigators, their qualified designees, and sponsor staff at all times via an internet -based 
portal.  At intervals agreed to by  the vendor and Pfizer, these data will be transferred 
electronically  to Pfizer for anal ysis and reporting. 
Thee-diary  data do not need to be reported b y the investigator in the CRF.  However, if a 
subject withdraws because of prompted events reported in the e- diary , the event(s) should be 
recorded on the AE page of the CRF, regardless of whether the investigator considers the 
event(s) to be clinically  significant.
Investigators (or an appropriately  qualified designee) are required to review the e -diary  data 
online at frequent intervals (daily  is optimal) to evaluate subject compliance and as part of 
the ongoing sa fety review .
The investigator or designee must obtain stop dates for an y reactions ongoing on the last day 
that the e -diary  was completed.  The stop dates should be entered in the CRF at Visit 2.
7.1.2. Grading Scale for Prompted Events
The grading scales used i n this study  to assess 
prompted AEs as described below are based 
on concepts outlined in the Food and Drug Administration (FDA) Center for Biologics 
Evaluation and Research (CBER) guidelines on toxicity  grading scales for healthy  adult 
volunteers enrolled in preventive vaccine clinical trials.72
7.1.2.1. Local Reactions
From Day 1 through Day 10, where Day  1 is the day  of V accination 1, subjects will be asked 
to assess redness, swelling, and pain at the injection site and to record the sy mptoms in the 
e-diary  in the evening.  
Redness and swelling will be measured and recorded in measuring device units (range: 1 to 
21+), and then categorized during anal ysis as mild, moderate, or severe based on the grading 
scale in Table 2below.  Measuring device units can be converted to centimeters according to 
the following scale: 1 measuring device unit = 0.5 cm.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 41Pain at the vaccine injection site will be assessed by  the subject as mild, moderate, or severe 
according to the grading scale in Table 2.  A subject with a severe (Grade 3 or above) local 
reaction will be prompted to contact the investigator to assess the reaction and perform an 
unscheduled assessment or visit as appropriate. 
Only  an inve stigator is able to classify  a subject’s local reaction as Grade 4, after ph ysical 
examination of the subject or documentation from another medically  qualified source 
(eg, emergency  room or hospital record), or, in the case of pain at the injection site o nly, 
telephone contact with the subject.  If a subject experiences a Grade 4 local reaction, the 
investigator must immediately  notify  the sponsor .  Investigator sitestaff must educate the 
subject regarding signs and sy mptoms that would prompt investigator site contact. 
The procedure for notification of the sponsor is provided in the SRM or equivalent. 
Table 2. Grading Scales for Local Reactions
Mild
Grade 1Moderate
Grade 2Severe
Grade 3aGrade 4b
Redness
(synonym ouswith 
erythema)5 to 10 measuring 
device units 
=
2.5 to 5.0 cm11 to 20 measuring 
device units
=
5.5 to 10.0 cm21 measuring 
device units
=
10.5 cmNecrosis or exfoliative 
dermat itis
Swelling
(synonym ouswith 
edema)5 to 10 measuring 
device units
=
2.5 to 5.0 cm11 to 20 measuring 
device units
=
5.5 to 10.0 cm21 measuring 
device units
=
10.5 cmNecrosis
Pain at injection site Does not interfere 
with activityInterferes wit h 
activityPrevents daily 
activitycEmergency room visit 
or hospitalization
Abbreviations: CRF = case report form; e -diary = electronic diary.
Note: If the size of the redness and/or sw elling falls between 2 measuring device u nits, the higher measuring 
device unit number will be recorded in the e -diary.
a.Subjects experiencing Grade 3 local reactions will be asked to contact the investigator site.  In the event 
that the subject does not call, the investigator w ill call the subject.
b.Grade 4 assessment should be made by the investigator. Grade 4 w ill not be collected in the e -diary but as 
an AE on the CRF.  The severity of the local reaction should be graded usi ng the AE severity grading scale 
in Section 8.3. 
c.Prevents daily activity, ie, results in missed days of work or school or is otherwise incapacitating.
7.1.2.2. Systemic Events
From Day 1 through Day7, where Day  1 is the day  of V accination 1, subjects will be asked 
to assess headache, fatigue, muscle pain, and joint pain and to record the symptoms in the 
e-diary  in the evening.  The sy mptoms will be assessed by  the subject as mild, moderate, or 
severe according to the grading scale in Table 3below.  Subjects will also be instructed to 
contact investigator site staff if they  experience any  possible Grade 4 prompted sy stemic 
event (ie, emergency  room visit o r hospitalization for headache, fatigue, muscle pain, or joint 
pain) within 7 day s after vaccination.  Study  staff may  also contact the subject to obtain 
additional information on Grade 3 events entered into the e
-diary .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 42Only  an investigator is able to cla ssify  a subject’s sy stemic event as Grade 4, after ph ysical 
examination of the subject or documentation from another medically  qualified source 
(eg, emergency  room or hospital record) or telephone contact with the subject.  If a subject 
experiences a Grad e 4 systemic event, the investigator must immediately notify the sponsor. 
The procedure for notification of the sponsor is provided in the SRM or equivalent.
Table 3. Grading Scales for Systemic Events
Mild
Grade 1Moderate
Grad e 2Severe
Grade 3aGrade 4b
Fatigue 
(synonym ous
with tiredness)Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency r oom visit 
or hospitalization
Headache Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Muscle pain Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Joint pain Does not interfere 
with activitySome interference 
with activityPrevents daily routine 
activityEmergency room visit 
or hospitalization
Abbreviations: CRF = case report for m; e-diary = electronic diary.
a.Prevents daily routine activity ,ie, results in missed days of work or school or is otherw ise incapacitating.
b.Grade 4 assessment should be made by the in vestigator; Grade 4 w ill not be collected in the e -diary but will 
be collected as an AE on the CRF. The severity of the systemic event should be graded using the AE 
severity grading scale in Section 8.3.
7.1.2.3. Fever
In order to record information on fever, a digital thermometer will be given to the subject 
with instructions on how to measure oral temperature at home.  Temperature will be 
collected in the evening daily  for 7 day s following Vaccinat ion 1 (Day s 1 through 7, where 
Day 1 is the day  of vaccination) and at an y time during the 7 day s that fever is suspected.  
Fever is defined as an oral temperature of 100.4F (38.0C).  The highest temperature for 
each day  will be recorded in the e -diary .  In the event of a fever on Day  7, temperature will 
be collected daily  until fever has resolved (1 day  of temperature less than 100.4 F [38.0C]) 
in order to collect a stop date in the CRF.  A subject with a fever >104.0 F (>40.0C) will be 
prompted to c ontact the investigator to assess the fever.  Study  staff may  also contact the 
subject to obtain additional information if a temperature of >102 F is entered into an e -diary .  
Temperature will be measured and recorded to 1 decimal place and then grouped into ranges 
for the analy sis according toTable 4below. 
Table 4. Ranges for Fever
100.4F to 101.1F (38.0C to 38.4C)
101.2F to 102.0F (38.5C to 38.9C)
102.1F to 104.0F (39.0C to 40.0C)
>104.0F (>40.0C)

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 437.1.2.4. Use of Antipyretic/Pain Medication
From Day 1 through Day 7, where Day 1 is the day of Vaccination 1, the subject will be 
asked to record the use of antipyretic and/or pain medication used to treat symptoms (yes/no)in the e-diary in the evening.
7.2. Immunogenicity
Blood samples (approximately 30 or 50 mL/visit) for immunogenicity assessments will be 
collected from all subjects prior to Vaccination 1, prior to Vaccination 2(post-Vaccination 1/pre–Vaccination 2), approximately 1 month (28 to 35 days) after Vaccination 2, and approximately 1 year after Vaccination 1.  Sample collection, processing, storage, and shipping information can be found in the SRM or equivalent manual.
The total volume of blood collected from each subject completing participation through 
Visit 5 will be approximately 160 mL. Sera will be used for immunogenicity assessments and vaccine development research (eg, assay development to support vaccine programs).  
 
 
Immunogenicity assays will be performed at Pfizer Vaccine Research & Development 
Laboratory located at 401 North Middletown Road, Pearl River, NY 10965 and/or at a facility designated by Pfizer.
7.3. Biological Samples 
Blood samples will be used only for scientific research.  Each sample will be labeled with a 
code so that the laboratory personnel testing the samples will not know the subject’s identity.
Samples that remain after performing assays outlined in the protocol may be stored by Pfizer. 
Unless a time limitation is required by local regulations or ethical requirements, the samples will be stored for up to 15 years after the end of the study and then destroyed.  If allowed by the informed consent document, stored samples may be used for additional testing to better understand the immune responses to the vaccine(s) under study in this protocol, to inform the development of other products, and/or for vaccine-related assay work supporting vaccine programs.  No testing of the subject’s genetic material will be performed.  
The subject may request that his or her samples, if still identifiable, be destroyed at any time; 
however, any data already collected from those samples will still be used for this research.  The biological samples may be shared with other researchers as long as confidentiality is maintained and no testing of the subject’s genetic material is performed.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 448.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonserious AEs; and (3) exposure to the investigational product under study  during 
pregnancy  or breastfeeding, and occupational exposure.  
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form  to Pfizer Safety Within 24 
Hours of Awareness
SAE All All
Nonserious AEaAll None
Exposure to the investigational 
product under study during 
pregnancy or breastfeeding, and 
occupational exposureAll (regardless of whether 
associated with an AE), except 
occupational exposureExposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure (regardless 
of whether associated with an AE)
a.Nonserious AEs will be recorded from the time t he subject provides informed consent through and 
including Visit 3.  After Visit 3, only newly diagnosed chronic medical conditions (can be nonserious) and 
SAEs will be reported.
All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfizer Safety  on the CT SAE Report 
Form within 24 hours of awareness of the event b y the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his or her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information b oth to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF.  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination o f possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 45to Pfizer Safety . Any pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, any nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and und erstanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used o n both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject.  In addition, each s tudy subject will be questioned about the 
occurrence of AEs in a nonleading manner.
8.1.3. Withdrawal from the Study d ue to Adverse Events (see also the Subject 
Withdrawal Section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes,
according to the definition of AE noted b elow, and recorded on the CRF.
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirem ents section above.
8.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs and NDCMCs (“active 
collection period”) for each subject begins from the time the subject provides informed 
consent, which 
is obtained before the subject’s participation in the study  (ie, before 
undergoing an y stud y-related procedure and/or receiving investigational product), through 
and including Visit 3. Between Visit 3 and Visit 5, only  NDCMCs and SAEs will be 
reported. An NDCMC is defined as a disease or medical condition, not previously  identified, 
that is expected to be persistent or is otherwise long- lasting in its effects.  At Visit 4
(6months after V accination 1) , the subject will be contacted b y telephone to inquir e about 
SAEs, including hospitalizations and NDCMCs since Visit 3. At Visit 5 (12 months after 
Vaccination 1) , the subject will be asked about SAEs, including hospitalizations and 
NDCMCs since Visit 4.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 46For subjects who are screen failures, the active coll ection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be rep orted to Pfizer Safety .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigatio nal product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records.  
In addition, if the investigator dete rmines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE r eporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 478.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in physical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdos e;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 488.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when any of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; 
and/or
Test result leads to a change in study  dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered to be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, i n the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
AnSAE is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct norma l life functions);
Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 49Medical device complaints may  meet the SAE reporting requirement criteria (see the Medical 
Device Complaint Reporting Requirements section).  An incident is an y malfunction (ie, the 
failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly  or indirectl y, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deterioration in their state of health.  
A serious injury  that can cause a serious deterioration in state of health can include:
Alife-threatening illness, even if temporary  in nature;
Apermanent impairment of a bod y function or permanent damage to a body 
structure; 
Acondition n ecessitating medical or surgical intervention to prevent the above 
2bulleted items;
Examples: clinically  relevant increase in the duration of a surgical procedure; a 
condition that requires hospitalization or significant prolongation of existing 
hospitali zation;
Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the manufacturer’s instructions for use;
Fetal distress, fetal death, or an y congenital abnormality  or birth defects.
8.2.4. Hospital ization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to th e emergency  room visit is assessed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 50Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical exam ination);
Protocol -specified admission during a study  (eg, for a procedure required by  the study  
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a me dical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SA E 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Assessment
GRADE If required on the AE page of the CRF, the investigator w ill use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum i ntensity of the AE. For purposes of 
consistency, these intensity grades are defined as follows:
1 MILD Does not interfere with subject's usual function.
2 MODERATE Interferes to some extent with subject's usual function.
3 SEVERE Interferes signific antly with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) bu t would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 518.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previous sections, and will be handled as SAEs in 
the safet y database. 
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) ar e termed “tolerators,” while those who show transient liver injury  but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible " to 
progressive and serious liver injury , commonly  referred to as drug- induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a subject 
presents with clinical signs/sy mptoms, such LFT results should be managed and followed as 
described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab oratory
sample).  In rare instances, by  the time TBili elevations are detected, AST/A LT values might 
have decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law cri teria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baselin e values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 52oPreexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is smaller).
oPreexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 × ULN 
(which ever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory tests, detailed his tory, and physical assessmen t.
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), t otal bile 
acids, alkaline phosphatase ,and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further cont emporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over-the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and pot ential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of avail ability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product d uring Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pf izer Safety  within 24 hours of investigator 
awareness.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 538.4.3.1. Exposure d uring Pregnancy
For both unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
expose d (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
oAn example of environmental exposure would be a case involving direct contact with 
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
inves tigational product prior to or around the time of conception and/or is exposed during 
his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer prod uct in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the c ase of a live birth, the structural 
integrity  of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrity  of the terminated fet us should be assessed by  gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 54Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In a ddition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Re lease of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure d uring Breastfeeding
Scenarios of e xposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the e xposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertai n to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 558.4.4. Medication Errors and Lack of Efficacy
Other exposures to the investigational p roduct under study  may  occur in clinical trial settings, 
such as medication errors and lack of efficacy .
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form  to Pfizer Safety 
Within 24 Hours of Awareness
Medication errors and lack of 
effica cy.aAll (regardless of whether 
associated with an AE)Only  if associated with an 
SAE
a.For lack of efficacy (particularly for studies c onducted with vaccines, contraceptives, and products used 
in the treatment of life -threatening diseases or conditions [eg, anti -infectives]), see the Lack of Efficacy 
section below .
8.4.4.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength.  
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject;
The administration of expired investigational product;
The administration of an incorrect investigational product;
The administration of an incorrect d osage;
The administration of investigational product that has undergone temperature 
excursion from the specified storage range, unless it is determined by  the sponsor that 
the investigational product under question is acceptable for use.
Such medication er rors occurring to a study  participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medicat ion errors should be reported to Pfizer Safety  within 24 hours on a CT SAE Report 
Form only when associated with an SAE .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 568.4.4.2. Lack of Efficacy
Lack of efficacy  in an approved indication should be reported as an SAE to Pfizer Safety .
8.5.Medical Device Complaint Rep orting Requirements
All medical device complaints, regardless of whether the medical device complaint is 
associated with an AE, will be recorded on the applicable pages within the CRF.  This 
includes potential incidents or malfunctions associated with the use of a medical device 
product.  An incident or malfunction is an event that might have led to death or serious 
deterioration in health, or if it occurred again might lead to death or serious deterioration in 
health.
Pfizer is to be notified of all medic al device complaints within 24 hours of the investigator’s 
awareness of the event. 
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodolog y for summary  and statistical anal yses of the data collected in this study  
is outlined here and further detailed in a s tatistical analysis plan(SAP) , which will be 
maintained by  the sponsor.  The SAP may modify  what is outlined in the protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition s or their 
analyses will also be reflected i n a protocol amendment.
9.1.Sample Size Determination
The study  size is not based on any formal statistical hy pothesis test.  Approximately  220 
adults per vaccine group are planned to be randomized.  No formal statistical comparisons 
between vaccine groups are planned. Therefore, no power calculations for comparison of 
vaccine groups are included; however, the probabilities of at least 1 AEare calculated for 
range of assumed true event rates.
With approximately  200 subjects per vaccine group, the probabilitie s of observing at least
1AE, local reaction, or sy stemic event where the true rate is 0.1%, 0.5%, 1%, and  5% are 
0.198, 0.668, 0.890, and >0.999, respectivel y. 
9.2.Analysis Populations
The safet y population will include all subjects who receive 1 dose of 20 vPnC or 13vPnC.  
Subjects will be assigned to vaccine groups corresponding to the vaccine actually  received.  
The safet y population will be the only  anal ysis population for the primary  endpoints.  
The evaluable immunogenicity  population will generall y inc
lude an y subject :
1. who receives the assigned vaccine as randomized, 
2.whose has either Visit 2 or Visit 3 blood collection within 27 to 49 day s, inclusive, after 
vaccination, and

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 573. who has  OPA titers for at least 1 serotype for either the 
Visit 2 time point (which is 1 month after Vaccination 1) or the Visit 3 time point (which is 1 month after Vaccination 2); however, at least 1 nonmissing value must be obtained 27 to 49 days, inclusive, after the indicated vaccination.
A subject may be included in the evaluable population even if one of the Visit 2 or Visit 3 
blood collections is outside the window.  However, titers  obtained outside the window will be excluded from the evaluable population analysis.  Additional criteria (eg, without major protocol violations) are described in the SAP.
The evaluable immunogenicity population will be the primary analysis population for 
immunogenicity results.
The all-available immunogenicity population will include all subjects who receive 20vPnC or 
13vPnC and have  1 valid and determinate OPA titer  after either vaccination. The all-available immunogenicity population will be the secondary analysis population for immunogenicity results.  Subjects will be assigned to their randomized vaccine.
9.3. Immunogenicity Analysis
Geometric means (GMs) will be calculated for  OPA  results at every time point
by vaccine group, as well as the 95% confidence intervals (CIs). Each serotype will be analyzed separately.
GMFRs will be calculated for the OPA  results.  GMFRs will be calculated for 
change in value from before the first vaccination until 1 month after the first vaccination(Visit 2), from before the first vaccination (Visit 1) until 1 month after the second vaccination(Visit 3),  
  GMFRs will 
be defined as the latter result divided by the earlier result.
GMs and their confidence intervals (CIs) will be obtained by taking log transforms of titers 
, calculating the 95% CI with reference to the t-distribution, then 
exponentiating the mean and the limits. The GMFR and its CI will be calculated using the same method.
The proportions of subjects with OPA titers ≥the lower limit of quantitation (LLOQ) will be 
calculated for each time point and each serotype.  The 95% CIs will be obtained using the 
Clopper-Pearson method.CCI CCI
CCI
CCI CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 58Reverse cumulative distribution curves (RCDCs) will be compiled for each serotype.  The 
visits in each RCDC will depend on the serotype.  RCDCs for the 13 shared serotypes will be limited to before vaccination, 1 month after Vaccination 1,  
.  RCDCs for the additional 7 serotypes will be limited to before vaccination, 1 month after 
Vaccination 1 or 1 month after Vaccination 2 (depending on the investigational productsreceived), .  Further details will be specified in the SAP. 
9.4. Safety Analysis 
Descriptive statistics will be compiled for each safety endpoint for each vaccine group 
separately. In each group, local reactions and systemic events from Day 1 to Day 10 and from Day 1 to Day 7, respectively, after Vaccination 1 only, will be presented by severity and cumulatively across severity levels.  Descriptive statistics will include proportions of subjects with the indicated endpoint and the associated Clopper-Pearson 95% CIs.
AEs (including nonserious AEs, SAEs, and NDCMCs) with causality and severity will be 
summarized from Vaccination 1 until Visit 2, approximately 1 month (up to 35 days) after Vaccination 1. AEs will also be summarized from Vaccination 2 until Visit 3, approximately 2 months after 20vPnC (and 1 month after saline) administration in the 20vPnC/saline group, and 1 month after PPSV23 administration in the 13vPnC/PPSV23 group.  Additionally, SAEs and NDCMCs will be presented for 2 intervals: from Vaccination 1 until Visit 4(6 months after 20vPnC administration) and from Vaccination 1 until Visit 5 (12 months after 20vPnC administration).  The descriptive statistics for AEs will be summarized as the number and percentage of subjects reporting at least 1 event of each preferred term with the associated Clopper-Pearson 95% CIs, arranged by system organ class, and will also be summarized as the number of occurrences of the event.
9.5. Analysis Timing
1. Unblinded descriptive analyses of safety data for the first 30 subjects through 10 days of 
follow-up after Vaccination 1. These analyses will be performed by a designated unblinded statistician.
2. Unblinded safety and immunogenicity data from Visit 1 through Visit 2 will be analyzed 
when available.  The analyses will be descriptive.  This analysis will inform internal program development decisions and potentially support regulatory interactions.
3. Unblinded safety and immunogenicity data from Visit 2 to Visit 3 will be analyzed when 
available.  The analyses will be descriptive.  This analysis will also inform internal program development decisions and potentially support regulatory interactions.
4. Safety data from Visit 3 through Visit 4 (6-month telephone call) will be analyzed when 
available.
5. Safety  data from Visit 4 through Visit 5 will be analyzed when 
available. These will be the final analyses.CCI
CCI
CCI
CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 59There will be no alpha adjustments for these analyses.
Laboratory personnel directly conducting the immunogenicity assays will remain blinded 
until the last subject completes the 12-month visit.
 
 
 
 
 
 
 
 
10. QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during study conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may review source documents to confirm that the data recorded on CRFs are accurate.  The investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate regulatory authorities direct access to source documents to perform this verification.  This verification may also occur after study completion.
During study conduct and/or after study completion, the investigator site may be subject to 
review by the institutional review board (IRB)/ethics committee (EC), and/or to quality assurance audits performed by Pfizer, or companies working with or on behalf of Pfizer, and/or to inspection by appropriate regulatory authorities.
The investigator(s) will notify Pfizer or its agents immediately of any regulatory inspection 
notification in relation to the study. Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its agent, whenever feasible, to be present during the inspection.  The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the subject's medical records.  The investigator will promptly provide copies of the inspection findings to Pfizer or its agent.  Before response submission to the regulatory authorities, the investigator will provide Pfizer or its agents with an opportunity to review and comment on responses to any such findings.CCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 60It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulato ry 
authorities, without written permission from Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,
and available when required.  The 
CRFs must be signed by  the investigator or by  an authorized staff member to attest that the 
data contained on the CRFs are true. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry . 
In most cases, the source documents are the hospi tal or the ph ysician subject chart.  In these 
cases , data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity  of all participating subjects 
(sufficient information to link records, eg,CRFs and hospital records), all original signed 
informed consent documents
, copies of all CRFs, safet y reporting forms, source docum ents, 
and detailed records of treatment disposition, and adequate documentation of relevant 
correspondence ( eg,letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICH guidelines, acco rding to local 
regulations, or as specified in the c linical study agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer. 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 61Investigator records must be kept for a minimum o f 15 y ears after completion or 
discontinuation of the study or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg,
recruitment advertisemen ts, if applicable, from the I RB/EC.  All correspondence with the
IRB/EC should be retained in the investigator f ile.  Copies of IRB/EC approvals should be 
forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Research Involving Human Subjects (Council for International Organizations of 
Medic al Sciences [CIOMS] 2002), ICH Guideline for G ood Clinical Practice , and the 
Declaration of Helsinki .
12.3. Subject Information and Consent
All parties will ensure protection of subject personal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where
required b y law.
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
name s, address es, and other identifiable data will be replaced b y numerical code s based on a 
numbering sy stem provided by  Pfizer in order to de -identify  study  subject s.The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’s numerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subject
s’personal data consistent 
with applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must be in 
compliance w ith ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 62The informed consent document s used during the informed consent process and an y subject 
recruitment materials must be reviewed and approved by  Pfizer , approved by  the IRB/EC
before use , and available for inspection
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y and possible risks associated with participation.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before any  study -specific activity  is performe d.The investigator 
will retain the original of each subject's signed consent document .
12.4. Reporting of Safety Issues and 
Serious B reaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influen ce the evaluation of the benefits and risks of the investigational 
product, Pfizer s hould be informed immediately .
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study sub jects against any  immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in the Participating Country
End of trial in all participating countries is defi ned as last subject last visit (LSLV).  After 
this time, sites will be closed out, the I RB/EC will be informed, and no further CIOMS 
reports will be sent.
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulator y authority  decision, 
change in opinion of the IRB/EC , orinvestigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
20vPnC at any  time.
If a stud y is prematurel y terminated
, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 30 day s.  As directed b y Pfizer, all study materials must be collected 
and all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly
 disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (Clini calTrials.gov), the European Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 63In all cases, stud y results are reported b y Pfizer in an objective, accurate, balance d, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventiona l studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary  completion dat e (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the pri mary  outcome, whether the clinical study  
concluded according to the pre specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requireme nts.  EU Basic Results are submitted 
for posting within 1 y ear of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov
.
15.2. Publications by I nvestigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the 
PI of the results of the s tudy based on information collected or generated by  the PI , whether 
or not the results are favorable to the Pfizer product.  However, to ensure aga inst inadvertent 
disclosure of confidential i nformation or unprotected inventions, the i nvestigator will provide 
Pfizer an opportunity  to review an y proposed publication or other t ype of disclosure of the 
results of the study (collect
ively , “publication”) before it is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 day s before it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intell ectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 day s.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 64The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfizer product -related information 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results.
If the study  is part of a multi centerstudy , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publications 
bythe 
PIwill reference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of co mpletion or termination of the s tudy at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the s tudy, 
the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the C SA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA will control as to all other 
issues.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 6516.REFERENCES
1Said MA, Johnson HL , Nony ane BA, Deloria -Knoll M, O’Brien KL ;for 
the AGEDD Adult Pneumococcal Burden Study  Team . Estimating the 
burden of pneumococcal pneumonia among adults: a sy stematic review 
and meta -analysis of diagnostic techniques. PLoS One . 
2013;8(4):e60273.
2O'Brien KL, Wolfson L J, Watt JP, et al. Burden of disease caused b y 
Streptococcus pneumoniae in children younger than 5 years: global 
estimates. Lancet . 2009;374(9693):893-902.
3Huang SS, Johnson KM, Ray  GT, et al. Healthcare utilization and cost of 
pneumococcal disease in the United States. Vaccine .
2011;29(18):3398 -3412.
4Iyer AS, Ohtola JA, Westerink MAJ . Age -related immune response to 
pneumococcal poly saccharide vaccination: lessons for the clinic. Expert 
Rev Vaccines. 2015;14(1):85 -97.
5Knoll MD, Clark S, Portnoy  A, Roberts C, Ozawa S . Prelimina ry 
estimates of adult pneumococcal disease burden in the United States in 
the post 13
-valent pneumococcal conjugate vaccine (PCV -13) era. Poster 
presented at ISPPD, 2016; Glasgow, Scotland.
6JainS, Williams DJ, Arnold SR, et al ; for the CDC EPI C Study  Team.
Community -acquired pneumonia requiring hospitalization among U.S. 
children. N Engl J Med. 2015;372(9):835 -845.
7JainS, Self WH, Wunderink RG, et al; for the CDC EPI C Study  Team.
Community -acquired pneumonia requiring hospitalization among U.S. 
adult s. 
N Engl J Med. 2015;373(5):415 -427.
8Active Bacterial Core Surveillance (ABCs) Report, Emerging I nfections 
Program Network, Streptococcus pneumoniae , 201 5. 
http://www.cdc.gov/abcs/reports -findings/survreports/spneu15.pdf. 
Accessed 14 Jul 2017.
9World H ealth Organization. 23 -valent pneumococcal poly saccharide 
vaccine. WHO position paper. Wkly Epidemiol Rec . 
2008;83( 42):373-
384.
10Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their 
types: past, present, and future. Clin Microbiol Rev . 2015;28(3):871-899.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 6611Hausdorff WP, Hanage WP. I nterim results of an ecological
experiment -conjugate vaccination against the pneumococcus and 
seroty pe replacement. Hum Vaccin Immunother. 2016;12(2):358 -374.
12Alonso DeVelasco E, Verheul AFM, Verhoef J, Snipp e H. Streptococcus 
pneumoniae : virulence factors, pathogenesis, and vaccines. Microbiol 
Rev. 1995;59(4):591 -603.
13Prevention of pneumococcal disease: recommendations of the A dvisory  
Committee on I mmunization Practices (ACIP). MMWR Recomm Rep.
1997; 46(R R-8):1-24.
14Austrian R.A brief history  of pneumococcal vaccines. Drugs Aging.
1999;15(s uppl 1 ):1-10.   
15Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy  of 
polyvalent pneumococcal poly saccharide vaccine. N Engl J Med.
1991;325(21):1453 -1460.
16Stein KE. Thy mus- independent and thy mus
-dependent responses to 
polysaccharide antigens. J Infect Dis. 1992;165 Suppl 1:S49 -S52.
17Borrow R, Health PT, Siegrist CA. Use of pneumococcal poly saccharide 
vaccine in children: what is the evidence? Curr Opin I nfect Dis.
2012;25(3):292 -303.
18Jackson LA, Neuzil KM, Yu O, et al ; for the Vaccine Safet y Datalink.
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N 
Engl J Med. 2003;348(18):1747-1755.
19Leventer -Roberts M, Feldman BS, Brufman I , Cohen -Stavi CJ, Hoshen 
M, Balicer RD. Effectiveness of 23 -valent pneumococcal polysaccharide 
vaccine against invasive disease and hospital -treated pneumonia among 
people aged  65 years: a retrospective case -control study . Clin Infect Dis . 
2015;60(10):1472 -1480.
20Wright PF, Sell SH, Vaughn WK, Andrews C, McConnell KB, 
Schiffman G. Clinical studies of pneumococcal vaccines in infants. II. 
Efficacy  and effect on nasophary ngeal carriage. Rev Infect Dis. 1981;3 
Suppl:S108 -S112.
21Greenberg RN, Gurtman A, Frenck RW, Strout C, et al. Sequential 
administration of 13-
valent pneumococcal conjugate vaccine and 23-
valent pneumococcal poly saccharide vaccine in pneumococcal vaccine -
naive adults 60 -64 years of age. Vaccine. 2014;32(20):2364-2374.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 6722Jackson LA, Gurtman A, v an Cleeff M, et al. Influence of initial 
vaccination with 13 -valent pneumococcal conjugate vaccine or 23 -valent 
pneumococcal poly saccharide vaccine on anti -pneumococcal responses 
following subsequent pneumococcal vaccination in adults 50 y ears and 
older. V accine. 2013;31(35):3594-3602.
23Torling J, Hedlund J, Konradsen HB, Ortqvist A. Revaccination with the
23-valent pneumococcal polysaccharide vaccine in middle -aged and 
elderl y persons previously treated for pneumonia. Vaccine.
2003;22(1):96 -103.
24Poolman J, Borrow R. Hyporesponsiveness and its clinical implications
after vaccination with poly saccharide or gl ycoconjugate vaccines. Expert 
Rev Vaccines
. 2011;10(3):307-322.
25Castiglia P. Recommendations for pneumococcal immunization outside
routine childhood immunization programs in Western Europe. Adv Ther. 
2014;31(10):1011 -1044.
26Updated recommendations for prevention of invasive pneumococcal 
disease among adults using the 23 -valent pneumococcal polysaccharide 
vaccine (PPSV23) . MMWR Morb Mortal Wkly Rep. 2010;59(34):1102 -
1106.
27Tomczy kS, Bennett NM, Stoecker C, et al; Centers for Disease Control 
and Prevention. Use of 13 -valent pneumococcal conjugate vaccine and 
23-valent pneumococcal poly saccharide vaccine among adults aged 65
years: recommendations of the Advisory  Committee on Immunization
Practices (AC IP). MMWR Morb Mortal Wkly Rep . 2014;63(37):822 -825.
28Torres A, Bonanni P, Hry niewicz W, Moutschen M, Reinert RR, Welte 
T.Pneumococcal vaccination: what have we learnt so far and what can 
we expect in the future? Eur J Clin Microbiol Infect Dis. 2015; 34(1):19
-
31.
29Robinson KA, Baughman W, Rothrock G, et al ; for the Active Bacterial 
Core Surveillance (ABCs)/Emerging Infections Program Network . 
Epidemiology  of invasive Streptococcus pneumoniae infections in the 
United States, 1995- 1998: opportunities for prevention in the conjugate 
vaccine era. JAMA. 2001;285(13):1729-1735.
30Hausdorff WP, Bry ant J, Paradiso PR, 
Siber GR. Which pneumococcal 
serogroups cause the most invasive disease: implications for conj ugate 
vaccine formulation and use, part I. Clin Infect Dis. 2000;30(1) :100-121.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 6831Hausdorff WP, Bry ant J, Kloek C, Paradiso PR, Siber GR . The 
contribution of specific pneumococcal serogroups to different disease 
manifestations: implications for conjugate v accine formulation and use, 
part II. Clin Infect Dis . 2000;30 (1):122-140.
32Nuorti JP, Whitney  CG. Prevention of pneumococcal disease among 
infants and children -use of 13-valent pneumococcal conjugate vaccine 
and 23
-valent pneumococcal pol ysaccharide vac cine - recommendations 
of the Advisory  Committee on Immunization Practices (ACI P). MMWR 
Recomm Rep. 2010.59(R R-11):1-18.
33Johnson HL , Deloria -Knoll M, L evine OS, et al. Sy stematic evaluation of 
seroty pes causing invasive pneumococcal disease among childre n under 
five: the Pneumococcal Global Seroty pe Project. PLoS Med.
2010; 7(10):1-13.
34Richter SS, Heilmann KP, Dohrn CL , 
Riahi F, Diekema DJ, Doern GV . 
Pneumococcal serotypes before and after introduction of conjugate 
vaccines, United States, 1999 -2011. 
Emerg Infect Dis. 2013;19(7):1074 -
1083.
35Black SB, Shinefield HR, L ing S , et al. Effectiveness of heptavalent 
pneumococcal conjugate vaccine in children younger than five years of 
age for prevention of pneumonia. Pediatr Infect Dis J . 
2002;21(9):810 -815.
36Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent 
pneumococcal conjugate vaccine in children younger than 5 years of age 
for prevention of pneumonia: updated anal ysis using World Health 
Organization standardized interpretation of chest ra diographs . Pediatr 
Infect Dis J . 2006;25(9):779
-781.
37Cutts FT, Zaman SM, Enwere G, et al; Gambian P neumococcal Vaccine 
Trial Group. Efficacy  of nine -valent pneumococcal conjugate vaccine 
against pneumonia and invasive pneumococcal disease in The Gambia: 
randomised, double -blind, placebo -controlled trial. Lancet.
2005; 365(9465):1139
-11 46.
38Eskola J, Kilpi T, Palmu A, et al ; for the Finnish Otitis Media Study  
Group. Efficacy  of a pneumococcal conjugate vaccine against acute otitis 
media. N Engl J Med. 2001 ;344(6):403-409.
39O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safet y of seven -
valent conjugate pneumococcal vaccine in American Indian children: 
group ran domised trial. Lancet. 2003;362(9381):355-361.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 6940Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce 
N; for the Vaccine Trialists Group. A trial of a 9- valent pneumococcal 
conjugate vaccine in children with and those without HIV infection. 
NEngl J Med. 2003;349(14):1341-
1348.
41Whitney  CG, Farley  MM, Hadler J, et al ; for the Active Ba cterial Core 
Surveillance of the Emerging I nfections Program Network . Decline in 
invasive pneumococcal disease after the introduction of protein-
polysaccharide conjugate vaccine. N Engl J Med. 
2003;348(18) :1737 -1746
.
42Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core 
Surveillance/Emerging Infections Program Network. Sustained 
r
eductions in i nvasive pneumococcal disease in the era of c onjugate 
vaccine .J Infect Dis. 2010; 201(1):32-41.
43Reinert RR, Paradiso P, Fritzell B. Advances in pneumococc al vaccines: 
the 13
-valent pneumococcal conjugate vaccine received market 
authorization in Europe. Expert Rev Vaccines . 2010;9(3):229 -236.
44Bonten MJM, Huijts SM, Bolkenbaas M,et al. Polysaccharide c onjugate 
vaccine against p
neumococcal pneumonia in adults. N Engl J Med .
2015;372(12) :1114 -
1125.
45Centers for Disease Control and Prevention. Licensure of a 13 -valent 
p
neumococcal conjugate vaccine (PCV13) and recommendations for use 
among children -- Advisory Committee on Immunizatio n Practices 
(ACI P), 2010
.  MMWR Morbid Mortal Wkly Rep. 2010; 59(9) :258-261.
46Centers for Disease Control and Prevention. Licensure of 13 -valent 
pneumococcal conjugate vaccine for adults aged 50 y ears and older.  
MMWR Morb Mortal Wkly Rep .2012;61(21):394 -395.
47Prevenar 13 Summa ry of Product Characteristics. 
http://www.ema.europa.eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/human/001104/WC500057247.pdf. Accessed 
12 Sep 2016.
48European Medicines Agency . Prevenar 13 Assessment Report. 
22January  2015.  
http://www.ema. europa.eu/docs/en_GB/document_library /EPAR_ -
_Assessment_Report_ -_Variation/human/001104/WC500186805.pdf . 
Accessed 12 Sep 2016.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 7049World Health Organization. WHO Prequalified Vaccines. Pneumococcal 
(conjugate). Prevenar 13. https://extranet.who.int/gavi/PQ_W eb/Preview 
Vaccine.aspx?nav=0&ID=221. Effective 20 Aug 2010. Accessed 
12 Sep 2016.
50World Health Organization. WHO Prequalified Vaccines. Pneumococcal 
(conjugate). Prevenar 13 Multidose Vial. 
https://extranet.who.int/gavi/PQ_Web/PreviewVaccine.aspx?nav=0& ID=
317. Effective 14 Jul 2016. Accessed 12 Sep 2016.
51Harboe ZB , Dalby  T, Weinberger DM, et al. Impact of 13 -valent 
p
neumococcal conjugate vaccination in invasive p neumococcal disease 
incidence and m ortality [erratum appears in Clin Infect Dis. 
2014;59(12):1812] . 
Clin Infect Dis. 2014;59(8): 1066 -1073.
52Steens A ,Bergsaker MA, Aaberge IS, Ronnig K, Vestrheim DF . Prompt 
effect of replacing the 7 -valent pneumococcal conjugate vaccine with the 
13-valent vaccine on the epidemiology of invasive pneumococcal di sease 
in Norway . Vaccine. 2013 ;31(52) :
6232-623 8.
53Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness 
of the new serot ypes in the 13-valent pneumococcal conjugate vaccine. 
Vaccine. 2011; 29(49):9127-9131.
54Sherwin RL, Gray  S, Alexander R, et al. Distribution of 13 -valent 
pneumococcal conjugate vaccine Streptococcus pneumoniae serot ypes in 
US adults aged 
50 yearswith community -acquired pneumonia. J Infect 
Dis. 2013;208(11):1813-1820.
55Kobay ashiM, Bennett NM, Gierke R, et al. Intervals between PCV13 
and PPSV23 vaccines :
recommendations of the Advisory  Committee on
Immunization Practices (ACI P). MMWR Morb Mortal W kly Rep.
2015;64(34):944 -947.
56Moore MR, L ink-Gelles R, Schaffner W, et al. Effect of use of 13- valent 
pneumococcal conjugate va ccine in children on invasive pneumococcal 
disease in children and adults in the USA: analy sis of multisite, 
population -based surveillance. Lancet Infect Dis. 2015;15(3):301
-309.
57Waight PA, Andrews NJ, L adhani SN, Sheppard CL , Slack MPE, Miller 
E. Effect of the 13- valent pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 years after its 
introduction: an observational cohort study . Lancet Infect Dis . 
2015;15(5):535 -543.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 7158van der Linden M, Falkenhorst G, Perniciaro S, Im ohl M. Effects of 
infant pneumococcal c onjugate vaccination on s eroty pe distribution in 
invasive pneumococcal disease among c hildren and adults in German y. 
PLoS One. 2015;10(7):1 -17.
59Cohen R, Biscardi S, L evy C. Th e multifaceted impact of pneumococcal 
conjugate vaccine implementation in children in France between 2001 to 
2014. Hum Vaccines Immunother. 2016;12(2):277 -284.
60Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-
valent pne umococcal conjugate vaccine on pneumococcal 
nasophary ngea l carriage in children with acute otitis media. Pediatr 
Infect Dis J. 2012; 31(3):297 -301.
61Flasche S, Van Hoek AJ, Sheasby  E, et al. Effect of pneumococcal 
conjugate vaccination on seroty pe-specific carriage and in
vasive disease 
in England: a cross- sectio nal study . PLoS Med. 2011 ;8(4):e1001017.
62Williams SR, Mernagh PJ, L ee MH, Tan JT. Changing epidemiology  of 
invasive pneumococcal disease in Australian children after introduction 
of a 7 -valent pneumococcal conjugate vaccine. Med J Aust.
2011; 194(3):116-120.
63Lepoutre A, 
Varon E, Georges S, Gutmann L, Levy -Bruhl D. Impact of 
infant pneumococcal vaccination on invasive pneumococcal diseases in 
France, 2001-2006. Euro Surveill . 2008; 13(35) :18962.
64Munoz -Almagro C, Ciruela P, Esteva C, et al; for the Catala n Study  
Group of Invasive Pneumococcal D isease .Seroty pes and clones causing 
invasive pneumococcal disease before the use of new conjugate vaccines 
in Catalonia, Spain. J Infect. 2011
;63(2):151-162.
65Norton NB, Stanek RJ, Mufson MA. Routine pneumococcal v
accination 
of children provokes 
new patterns of s eroty pes causing invasive 
pneumococcal disease in adults and c hildren. Am J Med Sci.
2013;345(2):112-120.
66Adam HJ, Karlowsky  JA, Nichol KA, et al. Baseline epidemiology  of 
Streptococcus pneumoniae serot ypes in Canada prior to the introduction 
of the 13
-valent pneumococcal vaccine. Microb Drug Resist.
2012; 18(2):176-182.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 7267Gonzalez BE, Hulten KG, L amberth L, Kaplan SL, Mason EO Jr; U.S. 
Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus 
pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal 
infections in children in the United States after the introduction of the 
pneumococcal 7 -valent conjugate vaccine. Pediatr Infect Dis J.
2006; 25(4):301-305.
68Harboe ZB, 
Thomsen RW, Riis A, et al. Pneumococcal serot ypes and 
mortality  following invasive pneumococcal disease: a population -based 
cohort study . PLoS Med. 2009; 6(5):e1000081.
69Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and 
antibiotic resistance in young children before 13- valent conjugate 
vaccine. 
Pediatr Infect Dis J. 2012; 31(3):249-254.
70Cohen 
R, Varon E, Doit C, et al . A 13- year survey of pneumococcal 
nasophary ngeal carriage in children with acute otitis media following 
PCV7 and PCV13 implementation. Vaccine . 2015;33(39):5118-5126.
71Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the 
second -generation pneumococcal capsular pol ysaccharide vaccine with 
emphasis on the cross- reactive t ypes within groups. J Infect Dis.
1983;148(6):1136 -1159.
72Food and Drug Administration, C enter for Biologics Evaluation and 
Research. Toxicity  Grading Scale for Healthy  Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. Guidance for 
Industry , September 2007.

20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 73Appendix 1.
The following is a list of abbreviations that may be used in the protocol. 
Abbreviation Term
13vPnC 13-valent pneumococcal conjugate vaccine
20vPnC 20-valent pneumococcal conjugate vaccine
ACIP Advisory Committee on Immunization Practices
AE adverse event
ALT alanine aminotransferase
AOM acute otitis media
AST aspartate aminotransferase
CAP community-acquired pneumonia
CAPiTA Community-Acquired Pneumonia Immunization Trial in Adults
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
COPD chronic obstructive pulmonary disease
CRF case report form
CRM 197 cross-reactive material 197
CSA clinical study agreement
CT clinical trial
DILI drug-induced liver injury
DU dispensable unit
EC ethics committee
e-diary electronic diary
E-DMC external data monitoring committee
EDP exposure during pregnancy
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GM geometric mean
GMFR geometric mean fold rise
GMT geometric mean titer
HIV human immunodeficiency virus
IB investigator’s brochure
ICH International Council for HarmonisationCCI
20-valent Pneumococcal Conjugate Vaccine (20vPnC)
B7471002
Final Protocol, 20 July 2017
Page 74Abbreviation Term
ID identification
IgG immunoglobulin G
IND investigational new drug application
INR international normalized ratio
IP investigational product
IPD invasive pneumococcal disease
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IWR interactive Web -based response
LFT liver function test
LLOQ lower limit of quantitation
LSLV last subject last visit 
N/A not applicable
NDCMC newly  diagnosed chronic medical condition
OPA opsonophagocy tic activity
PCD primary  completion date
PDA personal digital assistant
PI principal investigator
PPSV23 23-valent pneumococcal poly saccharide vaccine
PT prothrombin time
RCDC reverse cumulative distribution curve
SAE serious adverse event
SAP statistical analy sis plan
SRM study  reference manual
SRSD single reference safet y document
TBili total bilirubin
ULN upper limit of normal
US United States
USPI US package insert
VT vaccine -type
WHO World Health Organization

'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH		

 
 
	  
	
'RFXPHQW 7LWOH  
  ! "#$#  % # % &#"%
% '%(   ") * %( '  "#% &#% "***# *")% &**    "#% +	 %") +( ' )
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\

$$
	 +2
233 '4. 55
6

$$
	 72+2	 -4./-- #4./ 55
6/
PPD
PPD